AU2010200034A1 - Fredericamycin derivatives - Google Patents

Fredericamycin derivatives Download PDF

Info

Publication number
AU2010200034A1
AU2010200034A1 AU2010200034A AU2010200034A AU2010200034A1 AU 2010200034 A1 AU2010200034 A1 AU 2010200034A1 AU 2010200034 A AU2010200034 A AU 2010200034A AU 2010200034 A AU2010200034 A AU 2010200034A AU 2010200034 A1 AU2010200034 A1 AU 2010200034A1
Authority
AU
Australia
Prior art keywords
cyclopenta
alkyl
rch
independently
trihydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2010200034A
Other versions
AU2010200034B2 (en
Inventor
Ulrich Abel
Werner Simon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zentopharm GmbH
Original Assignee
Zentopharm GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2003219088A external-priority patent/AU2003219088A1/en
Application filed by Zentopharm GmbH filed Critical Zentopharm GmbH
Priority to AU2010200034A priority Critical patent/AU2010200034B2/en
Publication of AU2010200034A1 publication Critical patent/AU2010200034A1/en
Application granted granted Critical
Publication of AU2010200034B2 publication Critical patent/AU2010200034B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

1 Fredericamycin derivatives The invention relates to novel fredericamycin derivatives, to drugs containing said derivatives or the salts thereof, and to the use of the fredericamycin derivatives for 5 treating diseases, particularly tumor diseases. Definition In the specification the term "comprising" shall be understood to have a broad 10 meaning similar to the term "including" and will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps. This definition also applies to variations on the term "comprising" such as "comprise" and "comprises". 15 Fredericamycin has been isolated 1981 from Streptomyces griseus, and demonstrates anti-tumor activity. Fredericamycin and some derivatives of fredericamycin are known. 20 In Heterocycles 37 (1994) 1893 - 1912, J. Am. Chem. Soc. 116 (1994) 9921 - 9926, J. Am. Chem. Soc. 116 (1994) 11275 - 11286, J. Am. Chem. Soc. 117 (1995) 11839 11849, JP 2000-072752, and in J. Am. Chem. Soc. 123 (2001), various total syntheses of fredericamycin A have been described, some being enantio-selective. 25 In US 4673768, alkali salts of the fredericamycin A are described. In US 4584377, fredericamycin derivatives are described, particularly derivatives acylated in ring E and F. In US 5,166,208, fredericamycin derivatives are described as well, particularly derivatives carrying thio and amino substituents in ring F. The derivatives are generated semi-synthetically or fully synthetically.
1A Surprisingly it was found that fredericamycin derivatives, especially those derivatized in ring A, represent potent drugs. Als6, a possibility was found to introduce such residues in ring A semi-synthetically, with which the water solubility and/or the 5 biological effect, the spectrum of action in comparison with fredericamycin, can be significantly increased. Furthermore, an alternative method was found to make fredericamycin and its derivatives water-soluble by generating cyclodextrin inclusion compounds. 10 The invention relates to novel fredericamycin derivatives with the general Formula Ia or lb: 2 O R5 R7 RisN. N2> 0 I R2a R6OHO ,R R6 0 R7 OH Y 0OR4 R1,N lb R3 wherein in each, RI means H, CI-C 6 alkyl, cycloalkyl, Ci-C 4 alkylcycloalkyl, R2 means H, Ci-CI 4 alkyl, C 2
-C
14 alkenyl, aryl, Ci-C 4 alkylaryl, heteroaryl, Ci-C 4 alkyl heteroaryl, C 2
-C
4 alkenylheteroaryl, cycloalkyl, Ci-C 4 alkylcycloalkyl, heterocycloalkyl,
CI-C
4 alkylheterocycloalkyl, CmH 2 m+opYp (with m = 1 to 6, for o = 1, p = 1 to 2m+o; for m = 2 to 6, o = -1, p = I to 2m+o; for m = 4 to 6, o = -2, p = 1 to 2m+o; Y = independently selected from the group consisting of halogen, OH, OR2 1, NH 2 , NHR2 1, NR2 1 R22, SH, SR21), (CH 2 )rCH 2 NHCOR21, (CH 2 )rCH 2 OCOR21, (CH 2 )rCH 2 NHCSR21,
(CH
2
),CH
2 S(O)nR21, with n = 0, 1, 2, (CH 2 )rCH 2 SCOR21, (CH 2 )rCH 2
OSO
2 -R21,
(CH
2 )rCHO, (CH 2 ),CH=NOH, (CH 2 )rCH(OH)R2 1, -(CH 2 )rCH=NOR2 1,
(CH
2 )rCH=NOCOR21, (CH 2 )rCH=NOCH 2 CONR2 1 R22,
(CH
2 )rCH=NOCH(CH 3 )CONR2 1 R22, -(CH 2 )rCH=NOC(CH 3
)
2 CONR2 1 R22,
(CH
2 )rCH=N-NHCO-R23, (CH 2 ),CH=N-NHC(O)NH-R23, (CH 2 )rCH=N-NHC(S)NH R23, (CH 2 )rCH=N-NHC(NH)NH-R23, (CH 2 )rCH=N-NHC(NH)-R23, (CH 2
),CH=N
NHCO-CH
2 NHCOR21, (CH 2 )rCH=N-0-CH 2 NHCOR21, (CH 2 )CH=N-NHCS-R23,
(CH
2 )rCH=CR24R25 (trans or cis), (CH 2 )rCOOH, (CH 2 )rCOOR21, (CH 2 )rCONR21R22, 3 N N R2U
-(CH
2 ),CH=NR21, (CH 2 )rCH=N-NR2 1 R22, 214, and the (CH 2 )r chain elongated residue (CH 2 )rCH=N-N-(C 3 NX'R21 1R212R213R214) (with X' = NR215, 0, S, and R21 1, R212, R213, R214, R215 being independently H or CI-C 6 alkyl), (CH 2 )rCH=N-NHSO 2 aryl, -(CH 2 )rCH=N-NHSO 2 heteroaryl, with r = 0, 1, 2, 3, 4, 5, preferably 0, R21, R22 are independently H, CI-C 14 alkyl, Ci-C 1 4 alkanoyl, CI-C 6 alkylhydroxy, C,
C
6 alkoxy, CI-C 6 alkylamino, CI-C 6 alkylamino-Ci-C 6 alkyl, CI-C 6 alkylamino-di-C i-C 6 alkyl, cycloalkyl, Ci-C 4 alkylcycloalkyl, heterocycloalkyl, CI-C 4 alkylheterocycloalkyl, aryl, aryloyl, CI-C 4 alkylaryl, heteroaryl, heteroaryloyl, CI-C 4 alkylheteroaryl, cycloalkanoyl, C 1
-C
4 alkanoylcycloalkyl, heterocycloalkanoyl, CI-C 4 alkanoylheterocycloalkyl, Ci-C 4 alkanoylaryl, CI-C 4 alkanoylheteroaryl, mono- and di sugar residues linked through a C atom which would carry an OH residue in the sugar, wherein the sugars are independently selected from the group consisting of glucuronic acid and its stereo isomers at all optical atoms, aldopentoses, aldohexoses, including their desoxy compounds (as e.g. glucose, desoxyglucose, ribose, desoxyribose), or R21 and R22, together with the N, form a ring with 4, 5, 6, 7, or 8 members, which may optionally contain still another heteroatom selected from the group N, 0, S, R23 independently of R21, has the same meanings as R21, or CH 2 -pyridinium salts,
CH
2 -tri-Ci-C 6 alkylammonium salts, CONH 2 , CSNH 2 , CN, CH 2 CN, R24 independently of R21, has the same meanings as R21, or H, CN, COCH 3 , COOH, COOR21, CONR21R22, NH 2 , NHCOR21, R25 independently of R21, has the same meanings as R21, or H, CN, COCH 3 , COOH, COOR21, CONR21R22, NH 2 , NHCOR21, 4 R24, R25 together with the N, form a ring with 4, 5, 6, 7, or 8 members, which may optionally contain still another heteroatom selected from the group N, 0, S, R3 means H, F, Cl, Br, I, OH, OR3 1, NO 2 , NH 2 , NHR3 1, NR3 1 R32, NHCHO, NHCOR3 1, NHCOCF 3 , CH 3 -mhalm (with hal = Cl, F, particularly F, and m = 1, 2, 3), OCOR31, R31, R32 are independently C 1
-C
6 alkyl, or R31 and R32, together with the N, form a ring with 4, 5, 6, 7, or 8 members, which may optionally contain still another heteroatom selected from the group N, 0, S, R5 means H, C 1
-C
20 alkyl, cycloalkyl, C 2
-C
2 0 alkenyl, C 2 -Cio alkinyl, Ci-C 4 alkyl cycloalkyl, heterocycloalkyl, CI-C 4 alkyl heterocycloalkyl, aryl, Ci-C 4 alkylaryl, heteroaryl, Ci-C 4 alkylheteroaryl, CmH 2 m+o-pYp (with m = 1 to 6, for o = 1, p = I to 2m+o; for m= 2 to 6, o = -1, p = 1 to 2m+o; for m = 4 to 6, o = -2, p = I to 2m+o; Y = independently selected from the group consisting of halogen, OH, OR5 1, NH 2 , NIHR5 1, NR51R52, SH, SR21), (CH 2 )sCH 2 NHCOR51, (CH 2 )sCH 2 NHCSR51,
(CH
2 )sCH 2 S(O)nR5 1, with n = 0, 1, 2, (CH 2 )sCH 2 SCOR51, (CH 2 )sCH 2 OCOR51,
(CH
2 )sCH 2
OSO
2 -R5 1, (CH 2 )sCH(OH)R51, (CH 2 )sCOOH, (CH 2 )sCOOR5 1,
(CH
2 )sCONR5 1R52, with s = 0, 1, 2, 3, 4, 5, preferably 0, mono- and di-sugar residues linked through a C atom which would carry an OH residue in the sugar, wherein the sugars are independently selected from the group consisting of glucuronic acid and its stereo isomers at all optical atoms, aldopentoses, aldohexoses, including their desoxy compounds (as e.g. glucose, desoxyglucose, ribose, desoxyribose), with the mono-sugar residues such as aldopentoses, aldohexoses, including their desoxy compounds (as e.g. glucose, desoxyglucose, ribose, desoxyribose) being preferred, with R5 1, R52 which are capable of independently adopting the meaning of R2 1, R22, R4, R6, R7 independently mean H, Ci-C 6 alkyl, CO-R41, R41 independently from R2 1, has the same meanings as R2 1, 5 X means 0, S, NH, N-R8, wherein R8 independently from R5 may adopt the same meaning as R5, or R5 and R8, together with the N, form a ring with 4, 5, 6, 7, or 8 members, which may optionally contain still another heteroatom selected from the group N, 0, S, or X-R5 may together be H, Y means 0, S, NR9, wherein R9 may be H or CI-C 6 alkyl, as well their stereoisomers, tautomers, and their physiologically tolerable salts or inclusion compounds, wherein the residues for Formula la may not concomitantly adopt the following meaning, except in case of cyclodextrin inclusion compounds: RI: H, CI-C 6 alkyl, R2: CI-C 6 alkyl, C 2
-C
6 alkenyl, R3: H, R4 and R6 identical, and independently H, Ci-C 6 alkyl, CO-R41, with R41 being Ci-C 6 alkyl, aryl, and R7 being H, CI-C 6 alkyl, Y: 0, and for Formula Ib: R1: H, R2: pentyl, 1-pentenyl, 3-pentenyl, 1,3-pentdienyl, R3: H, R4 and R6 being H, and X-R5 being methoxy, Y: 0. Preferably, the substituents do not concomitantly adopt the following meaning: RI, R3: H, R2: H, alkyl, hydroxyalkyl, particularly monohydroxyalkyl, alkoxyalkyl, CF 3 , (CH 2 )rCOOH, CHO, CONH 2 ,
(CH
2 )rCH 2 NHCO alkyl, (CH 2 )rCH 2 OCO alkyl, (CH 2 )rCH 2 NHCS alkyl, CH=NOH, CH=NO alkyl, aryl, alkylaryl, alkylheteroaryl, alkenyl, hydroxyalkenyl, particularly monohydroxyalkenyl, R4, R6, R7: H, alkyl, X-R5: H, R5: H, alkyl, aryl. Preferred are compounds of Formula Ila or Ilb 6 R1,N\ R2 R3 HO R6' R7 OH d o0 OR4 R1., 0 R2 R3 1 wherein the meaning of the residues R1-R41, X is as described above, their tautomers and their physiologically tolerable salts or inclusion compounds, wherein the residues for Formula Ia may not concomitantly adopt the following meaning, except in the case of cyclodextrin inclusion compounds: RI: H, CI-C 6 alkyl, R2: CI-C 6 alkyl, C 2
-C
6 alkenyl, R3: H, R4 and R6 identical, and independently H, C 1
-C
6 alkyl, CO-R41, with R41 being CI-C 6 alkyl, aryl, and R7 being H, CI-C 6 alkyl, Y: 0, and for Formula Ib: R1: H, R2: pentyl, 1 pentenyl, 3-pentenyl, 1,3-pentdienyl, R3: H, R4 and R6 being H, and X-RS being methoxy, Y: 0. The invention further relates to compounds of Formula Ia, Ib, Ila or IIb, in which the residues R, except for R2, have the above described meanings, and the water solubility of R2 is at least two times higher, preferably at least five timer higher, more preferred at least ten times higher, especially preferred at least fifty time higher, particularly one hundred times higher, or even five hundred times higher than of R2 being CH=CH-CH=CH-CH 3 , when all other residues are maintained. The increase in the water solubility is achieved e.g. by introduction of groups which can form additional hydrogen bonds, and/or are polar, and/or are ionic. A key intermediate are compounds with an aldehyde function in R2. For R2 preferred is also the group of the residues CmH2m+o-pYp (with m = 1 to 6, for o = 1, p = I to 2m+o; for m = 2 to 6, o = -1, p = I to 2m+o; for m = 4 to 6, o = -2, p = I to 2m+o; Y 7 = independently selected from the group of halogen, OH, OR2 1, NH 2 , NHR2 1, NR21 R22, SH, SR21), (CH 2 )rCH 2 NHCOR21, (CH 2 )rCH 2 0COR21, (CH 2 )rCH 2 NHCSR21,
(CH
2 )rCH 2 S(O)n-R21, with n = 0, 1, 2, (CH 2
)CH
2 SCOR21, (CH 2 )rCH 2
OSO
2 -R21,
(CH
2 )rCH(OH)R2 1, (CH 2 )rCOOH, (CH 2 )rCOOR2 1, (CH 2 )rCONR2 1 R22. Still particularly preferred is the group of the aldehyde-derived residues (CH 2 )rCHO, (CH 2 )rCH=NOH, (CH 2 )rCH=NOR2 1, (CH 2 )rCH=NOCOR2 1, (CH 2 )rCH=NOCH 2 CONR2 I R22,
(CH
2 ),CH=N-NHCO-R23, (CH 2 )rCH=N-NHC(O)NH-R23, (CH 2 )rCH=N-NHC(S)NH R23, (CH 2 )rCH=N-NHC(NH)NH-R23, (CH 2 )rCH=N-NHC(NH)-R23, (CH 2
),CH=N
NHCO-CH
2 NHCOR21, (CH 2 )rCH=N-0-CH 2 NHCOR21, (CH 2 )CH=N-NHCS-R23,
(CH
2 )rCH=CR24R25 (trans or cis), (CH 2 ),CH=NR21, (CH 2 )rCH=N-NR21R22, R NN N R," ,and the (CH 2 )r-chain elongated residue (CH 2
),CH=N-N
(C
3 NX'R21 1R212R213R214) (with X' = NR215, 0, S, and R21 1, R212, R213, R214, R215 being independently H or Ci-C 6 alkyl), -(CH 2 )rCH=N-NHSO 2 aryl, (CH 2 )rCH=N
NHSO
2 heteroaryl, (CH 2 )rCH=CH heteroaryl, with r = 0, 1, 2, 3, 4, 5, preferably 0. From the aldehydes and thereof derived compounds, such are preferred in which at least RI or r3 are not H, if R4 to R7 are H or alkyl. Preferred residues in R2 are further heteroaryl, cycloaryl, CI-C 4 alkylcycloalkyl, heterocycloalkyl, CI-C 4 alkyl heterocycloalkyl, CmH 2 m+o-pYp (with m = I to 6, for o = 1, p = I to 2m+o; for m = 2 to 6, o = -1, p = I to 2m+o; for m = 4 to 6, o = -2, p = I to 2m+o; Y = independently selected from the group of halogen, OH, OR21, NH 2 , NHR21, NR21R22, SH, SR21), CH 2 NHCOR21, CH 2 NHCSR21, CH 2 S(O)nR21, with n = 0, 1, 2,
CH
2 SCOR21, CH 2
OSO
2 -R21, CH(OH)R21, CH=NOCOR21, -CH=NOCH 2 CONR21R22,
-CH=NOCH(CH
3 )-CONR21R22, CH=NOC(CH 3
)
2 CONR 11R22, CH=N-NHCO-R23, CH=N-NHCO-CH 2 NHCOR21, CH=N-0-CH 2 NHCOR21, -CH=N-NHCS-R23, CH=CR24R25 (trans or cis), CONR21R22, -CH=NR21, -CH=N-NR21R22, RVi X~ H R X N R 24, with X' = NR215, 0, S, and R21 1, R212, R213, R214, R215 being independently H or Ci-C 6 alkyl), CH=N-NHSO 2 aryl, H=N-NHSO 2 heteroaryl.
8 Furthermore, compounds as described above are preferred, in which R3 means F, Cl, Br, I, OH, OR31, NO 2 , NH 2 , NHR31, NR31R32, NHCHO, NHCOR31, NHCOCF 3 , CH 3 -mhalm (with hal = Cl, F, particularly F, and m = 1, 2, 3), OCOR31, with the above described meanings for R31, R32. Also preferred are compounds as described above, in which X means N or S, especially when R3 is H or halogen, and/or R2 is alkenyl, particularly butadienyl or 1, 3-pentdienyl. Also preferred are compounds as described above, in which X-R5 is OH, and particularly their salts, and preferred in compounds of Formula Ia or Ila, since this acidic OH group may easily be deprotonized, which increases the water solubility and/or the biological efficacy. Furthermore preferred are still compounds as described above, wherein the residues R preferably independently adopt one or more of the following meanings: RI means H, CI-C 5 alkyl, cycloalkyl, especially H, R2 means CI-C 5 alkyl, CI-C 4 alkylaryl, C 2
-C
5 alkenyl, heteroaryl, CI-C 4 alkylheteroaryl, C 2
-C
4 alkenylheteraryl, CHF 2 , CF 3 , polyol side chain, particularly CHOH
CHOH-CHOH-CHOH-CH
3 , CHOH-CHOH-CH=CH-CH 3 , CH=CH-CHOH-CHOH-CH 3 ,
CH
2 Y (Y = F, Cl, Br, I), CH 2
NH
2 , CH 2 NR21R22, CH 2 NHCOR23, CH 2 NHCSR23,
CH
2 SH, CH 2 S(O)nR21, with n = 0, 1, 2, CH 2 SCOR21, particularly CH 2 OH, CH 2 0R21,
CH
2
OSO
2 -R21, particularly CHO, CH(OR21) 2 , CH(SR21) 2 , CN, CH=NOH, CH=NOR21, CH=NOCOR21, CH=N-NHCO-R32, CH=CR24, R25 (trans or cis), particularly COOH (particularly their physiologically tolerable salts), COOR2 1, CONR21 R22, -CH=NR2 1,
R
21 2 Ra N -CH=N-NR21R22, 2 , (with X' = NR215, 0, S, and R211, R212, R213, R214, R215 being independently H or Ci-C 6 alkyl), -CH=N-NHSO 2 aryl, -CH=N
NHSO
2 heteroaryl, CH=N-NHCO-R23, 9 R21, R22 independently mean CI-C 6 alkyl, cycloalkyl, aryl, CI-C 4 alkylaryl, heteroaryl, Ci-C 4 alkylheteroaryl, R23 independently of R21, has the same meanings as R21, or CH 2 -pyridinium salts,
CH
2 -tri-CI-C 6 alkylammonium salts, R24 independently of R21, has the same meanings as R21, or H, CN, COCH 3 , COOH, COOR21, CONR21R22, NH 2 , NHCOR21, R25 independently of R21, has the same meanings as R21, or H, CN, COCH 3 , COOH, COOR21, CONR21R22, NH 2 , NHCOR21, R24, R25 together mean C 4 -Cs cycloalkyl, R3 means F, Cl, Br, I, NO 2 , NH 2 , NHCOR31, R31 independently means CI-C 6 alkyl, R5 means H, CI-C 6 alkyl, particularly CI-C 3 alkyl, C 3 -Cs cycloalkyl, C 3
-C
8 cycloalkenyl, CI-C 6 alkenyl, Ci-C 6 alkinyls, Ci-C 4 alkylcycloalkyl, heterocycloalkyl, C 1 C 4 alkylheterocycloalkyl, aryl, Ci-C 4 alkylaryl, heteroaryl, Ci-C 4 alkylheteroaryl, CmH 2 m+o p (with m = 1 to 6, for o = 1, p = I to 2m+o; form =2 to 6,0 -1, p 1 to 2m+o; form = 4 to 6, o = -2, p = I to 2m+o; Y = independently selected from the group consisting of halogen, OH, OR21, NH 2 , NHR21, NR21R22, SH, SR21), particularly preferred is hydroxyalkyl with one or more OH groups, R4, R6, R7 independently means H, CI-C 5 alkyl, CO-R41, R41 independently from R2 1, has the same meanings as R2 1, X means 0, S, NH, N-R8, Y means 0, S, NH, 10 as well their stereoisomers, tautomers, and their physiologically tolerable salts or inclusion compounds, wherein the residues for Formula la may not concomitantly adopt the following meaning, except in case of cyclodextrin inclusion compounds: Ri: H, CI-C 6 alkyl, R2: CI-C 6 alkyl, C 2
-C
6 alkenyl, R3: H, R4 and R6 are identical, and independently are H, CI-C 6 alkyl, CO-R41, with R41 being CI-C 6 alkyl, aryl, and R7 being H, CI-C 6 alkyl, and for Formula Ib: RI: H, R2: pentyl, 1-pentenyl, 3-pentenyl, 1,3-pentdienyl, R3: H, R4 and R6 being H, and X-R5 being methoxy. 0, S, particularly 0, are preferred for Y. 0, NH, N-R8 are preferred for X. H, methyl, ethyl, propyl, particularly methyl, are preferred for R5. H, methyl, ethyl, propyl, particularly methyl, are preferred for R8.
OCH
3 , NH 2 , N(CH 3
)
2 are preferred for XR5. For R2 also preferred is the residue -CHOHCHOHCHOHCHOHCH 3 . Furthermore, the following residues are preferred for R2: -CHCH-2-methyl-4-thiazyl, particularly R , wherein R particularly is alkyl or NHCO alkyl, CH=NOR21, with R21 being methyl, ethyl, n-propyl, isopropyl, n-butyl, n-hexyl, benzyl, halogen benzyl, particularly fluorobenzyl and chlorobenzyl, -CH 2
CH
2 morpholinyl. Especially preferred are the compounds, the stereo isomers, tautomers, and physiologically tolerable salts or inclusion compounds of which, selected from the group consisting of the compounds of the examples and the compounds, demonstrate combinations of the various substituents of the examples.
1 Particularly preferred for R3 is H, F, Cl, Br, J, particularly F, Cl, Br, J. Particularly preferred for R2 is CI-C 8 alkyl, C 2
-C
8 alkenyl, CH=NORI, with R21 being Ci
C
8 alkyl, Ci-C 8 alkenyl, aryl or heteroaryl, CI-C 2 alkylaryl, particularly benzyl, Ci-C 2 alkylheteroaryl, wherein aryl or heteroaryl in particular have only one ring system which may be substituted once or twice with a substituent such as halogen, methyl, CF 3 , OH, OMe. Particularly preferred are derivatives of fredericamycin A in which only the above indicated, particularly preferred meanings of R2 and/or R3 are realized. The invention furthermore relates to drugs containing the above compounds of Formula I or II together with the usual carriers and adjuvants. Also preferred are the above mentioned drugs in combination with other agents for tumor treatment. These compounds according to the invention are used for preparation of drugs for treatment of tumors, particularly such that may be treated by inhibition of the topoisomerases I and/or II. Tumors that can be treated with the substances according to the invention are e.g. leukemia, lung cancer, melanomas, uterus tumors, prostate tumors and colon tumors. Also, fredericamycin A and its derivatives act against an unknown target in the cell cycle leading to apoptosis in tumor cells. Furthermore, the compounds according to the invention, and compounds which have concomitantly adopted the following meanings in Formula Ia: RI: H, CI-C 6 alkyl, R2: C 1 C 6 alkyl, C 2
-C
6 alkenyl, R3: H, R4 and R6 identically and independently H, CI-C 6 alkyl, CO-R41, with R41 being CI-C 6 alkyl, aryl, and R7 being H, Ci-C 6 alkyl, and in Formula Ib: RI: H, R2: pentyl, 1-pentenyl, 3-pentenyl, 1,3-pentdienyl, R3: H, R4 and R6 being H and X-R5 being methoxy, are used for preparation of drugs for treatment of neurodermitis, parasites and for immiunosuppression.
12 The invention also relates to a method for preparation of fredericamycin derivatives in which R2 as intermediate is -CHOHCHOHCHOHCHOHCH 3 . These compounds are preferably transformed into aldehydes for further derivatization. In the description and the claims, the substituents are described by the following definitions: The term "alkyl" by itself or as part of another substituent means a linear or branched alkyl chain radical of the respectively indicated length, in which optionally a CH 2 group may be substituted by a carbonyl function. Thus, CI.4 alkyl may be methyl, ethyl, 1-propyl, 2 propyl, 2-methyl-2-propyl, 2-methyl-1-propyl, 1-butyl, 2-butyl, C 1
-
6 alkyl, e.g. C 14 alkyl, pentyl, 1-pentyl, 2-pentyl, 3-pentyl, 1-hexyl, 2-hexyl, 3-hexyl, 4-methyl-1-pentyl, or 3,3 dimethylbutyl. The term "CI-C 6 alkylhydroxy" by itself or as part of another substituent means a linear or branched alkyl chain radical of the respectively indicated length which may be saturated or unsaturated, and which carries an OH group, e.g. hydroxymethyl, hydroxymethyl, 1 hydroxypropyl, 2-hydroxypropyl. The term "alkenyl" by itself or as part of another substituent means a linear or branched alkyl chain radical with one or more C=C double bonds of the respectively indicated length, several double bonds being preferably conjugated. Thus, C 2
-
6 alkenyl may for example be ethenyl, 1 -propenyl, 2-propenyl, 2-methyl-2-propenyl, 2-methyl-I -propenyl, 1 butenyl, 2-butenyl, 1,3-butdienyl, 2,4-butdienyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 1,3 pentdienyl, 2,4-pentdienyl, 1,4-pentdienyl, 1-hexenyl, 2-hexenyl, 1,3-hediexyl, 4-methyl I -pentenyl, or 3,3-dimethylbutenyl. The term "alkinyl" by itself or as part of another substituent means a linear or branched alkyl chain radical with one or more C-C triple bonds of the respectively indicated length. Thus, C 2
-
6 alkinyl may for example be ethinyl, 1-propinyl, 2-propinyl, 2-methyl-2-propinyl, 2-methyl-1-propinyl, 1-butinyl, 2-butinyl, 1,3-butdiinyl, 2,4-butdiinyl, 1-pentinyl, 2 pentinyl, 3-pentinyl, 1-hexinyl, 2-hexinyl, 4-methyl-I-pentinyl, or 3,3-dimethylbutinyl.
13 The term "halogen" stands for fluorine, chlorine, bromine, iodine, preferably bromine and chlorine. The term "NR21R22" preferably stands for a dialkylamino group, wherein the two alkyl groups together with the N can form a ring with 5 or 6 members with optionally one more heteroatom N or 0. The term "cycloalkyl" by itself or as part of another Substituent comprises unsaturated (mono or poly, preferably mono) or saturated, cyclic carbohydrate groups with 3 to 10 C atoms, preferably 3 to 8 C atoms, such as e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohex-2-enyl, cyclohex-3-enyl, cyclohex-2,4-dienyl, 4-methylcyclohexyl, 3-methylcyclohexyl, cycloheptyl or cyclooctyl. Saturated cycloalkyls are preferred. The cycloalkyls may be substituted with up to 3 substituents, preferably with up to 1 substituent, wherein the substituents independently can have the meaning CI-C 6 alkyl, OH,
NO
2 , CN, CF 3 , ORI1, SH, SRIi, CI-C 6 alkylhydroxy, CI-C 6 alkyl-ORI1, COOH, COOR1I, NH 2 , NHR1I, NR11R12, halogen, aryl, Ci-C 4 alkylaryl, heteroaryl, CI-C 4 heteroalkylaryl, wherein the residues R 11 und R12 independently can mean C I-C 10 alkyl, cycloalkyl, CI-C 4 alkylcycloalkyl. The term "heterocycloalkyl" by itself or as part of another substituent includes cycloalkyl groups, wherein up to two CH 2 groups may be substituted by oxygen, sulfur or nitrogen atoms, and one or two other CH 2 groups may be substituted by one or two carbonyl function(s), carbothionyl function(s), or a carbonyl function and a carbothionyl function, for example pyrrolidine, piperidine, morpholine or - N Y Y!CH2, S, 0. NH, NCI-C6-Alkyl The heterocycloalkyls may be substituted as with the cycloalkyls. The term "aryl" by itself or as part of another substituent includes aromatic ring systems with up to 3 rings, in which at least I ring system is aromatic, and those with up to 3 14 substituents, preferably up to 1 substituent, wherein the substituents independently can have the meaning C 1
-C
6 alkyl, OH, NO 2 , CN, CF 3 , ORI 1, SH, SRI 1, CI-C 6 alkylhydroxy,
CI-C
6 alkyl-ORI 1, COOH, COORI 1, NH 2 , NHR1 1, NR 11R12, halogen, wherein the residues RlI und R12 independently can mean Ci-Cio alkyl, cycloalkyl, CI-C 4 alkylcycloalkyl, or RI 1 and R12, together with the N, form a ring with 4, 5, 6, 7 or 8 members optionally containing still another heteroatom selected from the group N, 0, S. Apart from phenyl and 1-naphthyl and 2-naphthyl, preferred aryls are: I F I -oma I Oye~,Ne 0 meH 1 I- CFa C1% CH, The term "heteroaryl" by itself or as part of another substituent includes aromatic ring systems with up to 3 rings and with up to 3 identical or different heteroatoms N, S, 0, in which at least 1 ring system is aromatic, and those with up to 3 substituents, preferably up to 1 substituent, wherein the substituents independently can have the meaning C 1
-C
6 alkyl, OH, NO 2 , CN, CF 3 , ORI 1, SH, SRl l, C 1
-C
6 alkylhydroxy, C 1
-C
6 alkyl-ORI l, COOH, COORI 1, NH 2 , NHCORI 1, NHR1 1, NRI 1R12, halogen, or phenyl, wherein the residues R 11 und R12 independently can have the above indicated meanings. Preferred heteroaryls are: 15 H 0. C N N C1 $%-- (>QN The term "ring system" generally refers to rings with 3, 4, 5, 6, 7, 8, 9, or 10 members. Preferred are rings with 5 and 6 members. Furthermore, ring systems with one or 2 annelated rings are preferred. The compounds of Formula I may be present as such, or, if they contain acidic or basic groups, in the form of their salts with physiologically tolerable bases or acids. Examples for such acids are: hydrochloric acid, citric acid, trifluoracetic acid, tartaric acid, lactic acid, phosphoric acid, methane sulfonic acid, acetic acid, formic acid, maleic acid, fumaric acid, succinic acid, hydroxysuccinic acid, sulfuric acid, glutaric acid, aspartic acid, pyruvic acid, benzoic acid, glucuronic acid, oxalic acid, ascorbic acid, and acetylglycine. Examples for bases are alkali ions, preferably Na, K, particularly preferred the tri-potassium and tri sodium salts, alkaline earth ions, preferably C, Mg, ammonium ions. The compounds according to the invention may be administered orally in the usual way. The application may also be i.v., i.m., with vapors, or sprays through the nasopharynx. The dosage depends on age, condition and weight of the patient as well as on the type of application. Usually, the daily dose of the active ingredient per person is between 0.1 pLg/kg and I g/kg orally. This dosage may be given as 2 to 4 split dosages, or once per day as a slow release form.
16 The novel compounds may be used in the usual solid or liquid pharmaceutical application forms, e.g. as tablets, film tablets, capsules, powder, granules, coated tablets, solutions, or sprays. These are produced in the usual way. The agents can be processed with the usual pharmaceutical adjuvants such as tablet binders, fillers, preservatives, disintegrants, flow regulators, plasticizers, wetting agents, dispersants, emulsifiers, solvents, retardation agents, antioxidants, and/or propellants (see H. Sucker et al.: Pharmazeutische Technologie, Thieme-Verlag, Stuttgart, 1978). Usually, the so obtained application forms contain the active ingredient in amounts of 0.1 to 99 percent per weight. Experimental Part Fredericamycin A can be prepared by fermentation or fully synthetically according to the known methods. The reduced forms of the Formulas lb and Ilb can be obtained from the appropriate compounds of Formulas Ia and Ha using mild reducing agents. Preparation of the substances For synthesis of water soluble fredericamycin derivatives, fredericamycin (1) was first hydroxylized with osmium(IV)oxide at the diene side chain. The resulting compound (2) shows significantly higher water solubility compared to the original compound fredericamycin (1). In order to further increase the water solubility, (2) was transformed into the tri-potassium salt (3) (see diagram 1).
17 Diagram I DH OH Fredericaniycin (2) (1) b -a-K (3) a) OsO 4 , N-methylmorpholine-N-oxide, CH 2 , C1 2 , CH 3 0H, H20 b) KOH pyridine The fredericamycin tetrol (2) serves, among others, as an important intermediate for the synthesis of other fredericamycin derivatives with increased solubility and/or better action profile. By iodate cleavage with sodium periodate or carrier-bound periodate, the tetrol side chain may be degraded with very high yields to fredericamycin aldehyde (4) (see diagram 2). Diagram 2 Q 0 (4) a) NaIO 4
-H
2 0-DMF or carrier bound -10 4
-H
2 0-DMF 18 The fredericamycin aldehyde (4) can be reacted with acyihydrazones, hydroxylamine, and 0-alkylhydroxylamine to the appropriate hydrazone (see diagram 3), or oxime and oximether (see diagram 4). The reaction can be performed at room temperature in solvents such as DMF or pyridine, and is finished after a few minutes to hours. Synthesis of hydrazones Diagram 3 5 110 60 . 504.
H
0 0 R N' HO 41 O (4) (table 1/3) Table 1 Example/compound R m/e Xmax,(nm) 5/118 601.3 504.0 6/119 635.2 486.0 C1 0 0 'N' ~OH HN ~~0 R.0 4 19 R Compound Example 111 18 HNC 105 19 Cr H 113 20 O Synthesis of oximether Diagram 4
H~
0 ~ a .04 0 0 DMF (4) (table 2/3) Table 2 Example/compound R m/e Xma(nm) 7/122 -H 516.1 500.0 8/120 -CH 3 531.2 500.0 20 9/121 607.2 504.0 R-:2 10/123 678.1 504.0 HO OH OH 21/116 630.1 504.0 C' NC
H
2 Analogously, the compounds 100 - 242 can be generated according to the instructions below (table 3). The hereby used hydrazines, hydrazones and hydroxylamines are available commercially, or have been produced according to instructions known from the literature. Diagram 5 o ,A 0 ItRI R-1 (Rl= halogen, 1, Br, Cl) (table 3) 21 Table 3 Formula for table 3: RI HO Be 0OH 0 spiel/ Verbin Masse Masse dung R1 R2 berechnet gefunden UVMax Ausbeute 100 C5H5N2 H 592,1230 593,10 500 95 101 B-$-H C5H3F3N3 H 661,1056 662,11 500 95 102 NHH C6H5N20 H 620,1179 621,11 492 95 103 +H. C6H5N20 H 620,1179 621,11 500 95 22 104 N C2H2N3 H 567,1026 568,11 500 80 105 (19) N H C3H6N3 H 583,1339 584,10 492 95 106 0 NH H C5H4NO2 H 609,1019 610,09 492 95 107 0 NH C7H7N20 H 634,1335 635,13 492 95 108 H2NH NHCSNH2 H 574,0794 558,05 492 95 109 0 NH -H C5H4NOS H 625,0791 626,08 492 95 110 - H C1OH9N20 H 672,1492 673,15 492 95 23 111 N H C5H11N2 H 598,1699 599,14 492 95 112 D 0 C2H3N202 H 586,0971 587,10 492 95 113 (20) SO C3H2NOS2 H 631,0355 632,05 500 95 114 0 N
.
H C3H3N20 H 582,1022. 583,13 492 95 11-5
NH
2 0 HN
A
C7H7N20 H '634,1335 635,16 492 70 116
-A
C6H12NO2 H 629,1645 630,14 492 85 117 CH4N3 H 557,1182 558,11 500 95 24 118 -+-H 0 C4H9N20 H 600,1492 601,16 492 85 119 o' NH C7H8N20 H 635,1414 635,13 492 85 120(8) 0/ + OMe H 530,0961 531,12 492 90 121(9) 0H OCH2Ph H 606,1274 607,16 492 95 122(7) OH H 516,0804 517,11 482 95 123 (10) - .- 0 H So 0 H5
A
C6H1106 H 678,1332 679,14 500 95 124 0 C7H7N20 H 634,1335 635,15 492 95 25 125 0 NH +H
WA
NHCONH2 H 558,1022 559,12 492 95 126 HN 0 C7H13N20 H 640,1805 641,13 492 95 127 -- H 0 C7H6C10 H 640,0884 641,10 492 95 128 +H 0 NH C5H5N20S H 640,0900 641,10 492 95 129 7H o' N C5H6N30 H 623,1288 624,13 500 90 130 o NH C4H7N202 H 614,1284 615,13 492 95 131 C7H14N30 H 655,1914 656,19 492 50 26 132 0 NJ +H o NH C6H11N202 H 642,1597 643,17 492 60 133 H O NH
A
C3H7N20 H 586,1335 587,15 492 70 134 #-H
)
1 NH
A
C6H13N20 H 628,1805 629,17 492 70 135 -H C4H10NO H 587,1539 588,14 492 90 136 . f-H C13H18ClN20 H 752,1885 753,19 492 85 137 +H 0
A
C5H12NO H 601,1696 602,19 492 70 138 C5H5N2 Cl 626,0840 627,07 500 95 27 139 F F F
A
C5H3F3N3 Cl 695,0666 696,06 500 95 140 0 NH I C6H5N20 Cl '654,0789 655,07 500 95 141
N-
C6H5N20 Cl 654,0789 655,07 500 95 142 N---N Q aX N A-| C2H2N3 Cl 601,0636 602,06 500 90 143 CNH a C3H6N3 Cl 617,0949 618,08 500 95 144 0 C5H4NO2 Cl 643,0629 644,05 500 95 145 0 NH 1-6N H2N C7H7N20 Cl 668,0946 669,07 500 95 28 146 S NHCSNH2 Cl 608,0404 609,07 500 95 147 0 NH a3i C5H4NOS Cl 659,0401 660,07 500 95 14B C1OH9N20 Cl 706,1102 707,16 500 95 149 ax C5H11N2 Cl 632,1309 633,16 500 95 150 0 0 A C2H3N202 Cl 620,0582 621,09 500 95 151 C3H2NOS2 Cl 664,9965 645,31 500 95 152 0 aC6 C3H3N20 Cl 616,0633 617,10 500 95 29 153 0 a HN C7H7N20 Cl 668,0946 669,13 500 95 154 ONj C6H12NO2 Cl 663,1255 664,16 500 95 155 CH4N3 Cl 591,0792 592,11 500 95 156 C4H9N20 Cl 634,1102 635,14 500 95 157 C7H8N20 Cl 669,1024 669,12 500 95 158 OMe Cl 564,0571 565,09 500 95 159 0 OCH2Ph Cl 640,0884 641,12 500 95 30 160 HO OH Cl 550,0415 551,06 500 95 161 0 H5x C6H1106 Cl 712,0943 713,10 500 95 162 0 C7H7N20 Cl 668,0946 669,09 500 95 163 0 N-H NHCONH2 Cl 592,0633 593,07 500 90 164 ON O C7H13N20 Cl 674,1415 675,11 500 95 165 ax 0 C7H6ClO Cl 674,0494 675,03 500 90 166 C s C5H5N2OS Cl 67 4, 0510 675, 02 500 95 31 167 N N!1 0', NH C5H6N30 Cl 657,0898 658,06 500 90 168 NH o NH
A
C4H7N202 Cl 648,0895 649,07 500 95 169 C7H14N30 Cl 689,1524 690,15 500 60 170 00 .ao
A
C6H11N202 Cl 676,1208 677,13 500 60 171 H N S NH a C3H7N20 Cl- 620,0946 621,11 500 70 172 o N-. OiNHa C6H13N20 Cl 662,1415 663,12 500 70 173 aN 0
A
C4H1ONO Cl 621,1150 622,10 500 60 32 174 o C13H18ClN20 Cl 786,1495 787,16 500 90 175 )0 0 C5H12NO Cl 635,1306 636,10 500 75 176 Br C5H5N2 Br 670,0334 670,99 500 95 177 F F Br C5H3F3N3 Br 739,0161 739,99 500 95 178 0 NH A- Br N C6H5N20 Br 698,0284 699,00 500 90 179 /N Br HN0
A
C6H5N20 Br 698,0284 699,00 500 90 180 N-N N Br 65 C2H2N3 Br 645, 0130 645, 99 492 70 33 181 C-N NH BrI H C3H6N3 Br 661,0443 662,01 492- 95 182 0 NH Bi Br C5H4NO2 Br 687,0124 688,99 492 95 183 0 1-6N Brf
H
2
N
C7H7N20 Br 712,0440 713,03 500 95 184 S BrH NHCSNH2 Br 651,9899 653,04 500 95 185 0 NH Br Br C5H4NOS Br 702,9895 704,02 492 95 186 HN C1OH9N20 Br 750,0597 751,10 500 95 187 N Br3) C5H11N2 Br 676,0804 677,10 492 95 34 188 0 0Br C2H3N202 Br 664,0076 665,05 500 95 189 O S N Br C3H2NOS2 Br 708,9460 709,99 492 95 190 0 N~Br C3H3N20 Br 660,0127 661,05 492 95 191 SN H Br C7H7N20 Br 712,0440 713,08 492 70 192 193 ~ ~ ~ C61N2B00,07078 6 50 9 N 0 l Br C6H12NO2 B r 707,0750 708,06 500 95 193 FN -NHBr -) CH4N3 Br 635,0287 636,02 500 95 194 Br 0 C: C4H9N20 FRr 9Z7 35 195 0 Br C7H8N20 Br 713,0518 713,03 500 95 196 O Br OMe Br 608,0066 609,03 492 95 197 o Br OCH2Ph Br 684,0379 685,05 492 95 198 OH Br 593,9909 595-,01 492 95 199 D 0 o BrR 0 HDo
A
C6H1106 Br 756,0437 757,00 500 90 200 C7H7N20 Br 712,0440 713,00 500 90 201 0 HBr NHCONH2 Br 636,0127 637,00 492 90 36 202 N - Br HN C7H13N20 Br 718,0910 719,00 500 90 203 0 C7H6C1o Br 717,9989 718,00 492 95 204 s Br C5H5N2OS Br 718,0004 718,97 492 95 205 N C5H6N30 Br 701,0392 702,01 500 95 206 NH 3 o 1 NH B C4H7N202 Br 692,0389 693,03 492 95 207 Br C7H14N30 Br 733,1018 734,10 500 90 208 Br C6HllN202 Br 720,0702 721,10 500 95 37 209 H
N-
Br o;CNH C3H7N2Q. Br 664,0440 665,08 500 95 210 Br C6H13N20 Br 706,0910 707,09 500 90 211 N-. 0$Br-1 C4H1ONO Br 665,0644 666,08 500 95 212 Br C13H18C1N20 Br 830,0989 831,11 500 95 213 Br A C5H12NO Br 679,0801 680,09 492 95 214 $-H 0 Oi-Pr H 558,1274 559,21 500 99 215 -fH 0 x O-n-Hex H 600,1743 601,30 500 99 38 216 F -#H 0 C7H6FO H 624,1180 625,28 500 99 217 a C7H6C1O H 640,0884 641,27 500 99 218 F 0- H C7H6FO H 624,1180 625,31 500 99 219 0 Oi-Pr Cl 592,0884 593,28 500 80 220 0 0-n-Hex Cl 634,1354 635,36 500 90 221 F a+k 0 C7H6FO Cl 658,0790 659,32 500 85 222 C7H6C1O Cl 674,0494 675,31 500 80 39 223 F C7H6FO Cl 658,0790 659,34 500 80 224 Brk 0 Oi-Pr Br 636,0379 639,30 492 90 225 Bri O-n-Hex Br 678,0848 679,37 492 95 226 F B 0 C7H6FO Br 702,0284 703,34 492 95 227 C7H6C1O Br 717,9989 719,34 492 95 228 F Br+ C7H6FO Br 702,0284 705,35 492 95 229 '4 0 Oi-Pr I 684,0200 685,30 500 99.
40 230 0 0-n-Hex I 726,0669 727,41 500 99 231 F t '-4 0 C7H6FO I 750,0105 751,38 500 99 232 a C7H6C1O I 765,9810 767,36 500 99 233 F C7H6FO I 750,0105 751,38 500 99 234 O OCH2Ph I 732,0200 733,38 500 99 235 - - N C6H12NO2 I 755,0571 756,33 500 99 236 0 OMe 1 655,9887 657,32 492 95 41 237 0 C7H6C10 I 765,9810 767,38 492 99 238 C13H18ClN20 I 878,0810 879,45 500 99 239 HO llj' 4 OH I 641,9730 643,31 492 99 240 0 C7H14N30. I 781,0840 782,39 500 99 241 0 oNH C6H11N202 I 768,0523 769,38 500 99 242 0 0 C2H3N202 I 711,9897 713,37 500 99 42 Reduction and oxidation of fredericamycin aldehyde (4) Fredericamycin aldehyde (4) can be reacted with a common reducing agent such as sodium borohydrid in a solvent such as DMF or pyridine to hydroxymethyl fredericamycin (11). The reaction can be summarized as a single pot reaction (iodate cleavage of fredericamycin tetrol (2) to fredericamycin aldehyde (4) (see diagram 2) and reduction without isolation of the intermediates to fredericamycin alcohol (11)). Diagram 5 HN4HN Q 00 t H O H (4) (12) C b 40. IO 00 ti c 0 jQ 0 (13) a) NaClO 2 , NaH 2
PO
4 , 2,3-dimethylbutene-2 b) KOH, -H 2 0, DMF c) NaBH 4 Fredericamycin aldehyde (4) can be oxidized with the oxidizing agent sodium chlorite (NaClO 2 ), a buffer such as sodium dihydrogenphosphate in presence of an alkene such as 2,3-dimethylbutene with very good yields to fredericamycin carboxylic acid (12). The usually employed oxidation methods such as those being used in preparative chemistry for the oxidation of aldehydes to carboxylic acids (oxidation with chromium(VI) compounds, 43 manganese(VII) compounds as well as peroxo acid) did not lead to success. Only the use of the above described oxidation method provided the desired product. The literature describes oxidations of 2-pyridone-6-aldehydes with silver ions and potassium permanganate in an alkaline medium. This method, however, is not suited for fredericamycin and its derivatives since fredericamycin (1) contains base-labile (-reactive) groups (OH groups) causing undesired side reactions. The potassium salt of the fredericamycin acid (13) was obtained according to a common method by stoichiometric neutralization. Substitution in the B ring Fredericamycin (1) can be reacted with halogenation agents such as N-bromosuccinimide (NBS) and N-iodosuccinimide (NIS) with good yields to the substituted 5-bromo or 5-iodo fredericamycin derivatives (14) and (15) (diagram 6). The fredericamycin aldehyde (4) and (36) can be transformed with elemental bromine, NBS, BrI, NIS, and NCS to the appropriate halogen-substituted fredericamycin aldehyde (37), (38) and (39). The appropriate fluorine compound is accessible, too. Diagram 6 ix:" 2x . . HO 8a b Hal. Fredericamyc a) N-bromosuccinimide, DMF, 0* C; b) N-iodosuccinimide, DMF, 0* C; 44 (~ryC1 34 r DFD Natoj H HW M3 0 OH( 7 (4)H Fd rie m ciadey CN:)(39 1 3 34 NaF0 4 j Bo Both of the preuro foowngaioailne fredericamycioud (3 nd(4 ei ae as rcros (23)~~~~~~~~~ ithprcrofoanaioai-ikdfeeiayidrvAie 45 The preparation of (23) may be recognized as proof that the aldehyde (4) may be reacted with phosphorylides according to Wittig or Wittig-Horner (see diagram 7). Diagram 7 H 0100OH G N! H_ {4) (23) 0 a) ,Tofranthylguanldin The compound (24) is the precursor of an N-methylated fredericamycin derivative (diagram 8). Diagram 8 HOINQ .0 aa HMO 09 1) (24) a) H 3 1, K 2
CO
3 , DMF, RT 46 Fredericamycin may be transformed by palladium/hydrogen almost quantatively to tetrahydro fredericamycin (25), and may be halogenated in the nucleus according to the above described methods, e.g. to the bromine compound (26) (diagram 9): Diagram 9 0 Frederkamvyin 25 OH 26 Surprisingly it has also been found that the methoxy groups in fredericamycin and the derivatives according to the invention can be exchanged under alkali or earth alkali acetate catalysis by oxygen nucleophiles such as alcohols or polyols. Thereby, the alcohols can carry a multitude of different substituents (table 4). Diagram 10 R1 CtHcoome -- 47 0 OsR3 HO O HO O OH HN0 OH R1 R2 Table 4 5 Ausbeute Beispiel R1 R2 R3 UVmax. (nm) M/e (%) 243
H
3 C C 504 (M+H) 554 97 HaC H H 2 244
H
2 500 (M+)582 96
H
3 C,C C,'C H H2
H
2 245
H
3 CsHCH 3 500 (M+H)568 70 HaC H 246
H
2 504 (M+H)597 36 H HaC C,
CH
3 -7HCs - 504 (M+) 71 HaC Br H 2 632/634 248 H2 500 (M+H)566 91
H
2 C C H H H2 499 (M+) 569 52 HCH CH 2
H
2 HH 251 H2 500 (M+) 580 9 9 H3C, H C- 48 OH OH H3 . 499 (M+H) 622 20 SH H 2 OH OH 253
H
2 500 (M+H) 669 99 HC H H2Y 254
YH
3
H
2 504 (M+H) 653 48 H C' 2 0H N CC Ha HI H 2 H3, H CH 3 255 H r504 (M+H) 594 50 256 H 3C H H2 499 (M+H) 99 C C,'Br 632/634
H
2 Exchange of the methoxy group at the F ring The exchange of the methoxy groups at the F ring of the fredericamycin and at the derivatives is possible by primary, secondary or aromatic amines. Thereby, the components are stirred with the appropriate primary or secondary amines at room temperature in DMF or in another inert solvent. With aromatic amines, a catalysis with Lewis acids such as stannous(IV)chloride, etc. is required. Diagram 11 49 R2 O O R3 HO O R2NR3 HO O3 0 HO25 O HO OOH H O OH HN OHN R1 R1 R2 O R3 H HO OH HNO R1 Tabelle 5 R1 Beispiel R2,,N R3 H-N 257 H N258 Br H N259 H H N 260 H HN261 H NC 262 50 H H 3 C CH 3 263 H H-N CH 3 264
CH
3 H H265 HH CH 3 H N C H , 32 6 6 H 0 267 H H H 268 H 269 Br H"N 270 Preparation of heterocyclic fredericamycin derivatives 5 The fredericamycin aldehyde (4) can be reacted to pyridal acetone (271) according to Wittig or Wittig-Homer. Bromation with bromine in DMF yields the dibromo-derivative (272) substituted in the side chain and at the B ring. With the appropriately substituted thioamides or thioureas, the respective thiazole derivatives (273-276) are accessible. 10 51 Diagram 12 TMG(271) (4) DMF 1r, (272) TMG: Tetramethylguanidine Table 6 R Example
NH
2 273 Ph 274
CH
3 CONH 275
CH
3 276 Preparation of thioanalogoues of fredericamycin derivatives By sulfurization of fredericamycin or its derivatives with Lawesson reagent or P 4 Sio in pyridine, the derivatives analogous to thiopyridone are accessible (see diagram 13).
52 Diagram 13 04 fit Pydin RI RI: H, (277) Fredericamycin (1) forms inclusion compounds such as (25) with polysugars such as a cyclodextrin, that have good water solubility compared to the original substance. The dextrin inclusion compounds form easily if the components are mixed in the appropriate stoichiometric ratio in a suitable solvent such as DMSO (see diagram 11). *O Cyclodetin a 1 (1) (22) Biological activity against 12 cancer cell lines: LCL (H460, lung), MACL (MCF7, breast), LXFL (52L, lung), LXFA (629L, lung), MEXF (462NL, melanoma), MEXF (514L, melanoma), MAXF (40INL, breast), RXF (944L, renal), RXF (486L, renal), UXF (1 138L, uterus), PRXF (PC3M, prostate), PRXF (22RV 1). Efficacy (IC70) averaged over all cell lines in pg/mL at 5 test concentrations Table 7 53 Example / reference IC70 tg/mL adriamycin 0.0210 cisplatin 37.1020 fredericamycin 0.2790 1 0.1130 13 0.0050 14 0.0070 22 0.0080 23 0.0110 121 0.2020 127 0.1550 192 0.0750 196 0.0950 197 0.0340 198 0.2560 203 0.1590 212 0.2100 214 0.0220 215 0.0720 217 0.1290 218 0.0760 224 0.0470 225 0.1110 230 0.0910 232 0.3170 233 0.1000 234 0.0520 235 0.0810 236 0.1210 265 0.1330 275 0.3680 276 0.0840 54 Examples Example 1 1-Desoxy-5-C-[(8R)-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo 1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[gisoquinoline-8,2'-cyclopenta[b] naphthalene]-3-yl pentitol (2) Two hundred (200) mg (0.38 mmol) fredericamycin A (1) are dissolved in 30 mL dichloromethane. After addition of 20 mL methanol and 4.4 ml water, 350 mg (2.6 mmol) N-methylmorpholine-N-oxide are added. Under vigorous stirring, 0.2 ml of a 2.5% osmium(IV)oxide solution in t-butanol is added dropwise. The reaction mixture is acidified with 2-3 drops of trifluoracetic acid. After stirring for 48 hours, the reaction is complete according to HPLC control (RP18, acetonitrile water (0.2% acetic acid)). The reaction mixture is added to 400 ml water under vigorous stirring, and the dark red crystalline solid is sucked off through a filter. Drying in HV. Yield: 195 mg (87% of the theoretical value) dark red powder. ES-: M/e = 606.2 (M+-H), Xmax: 504.0. Example 2 Tri-potassium-1-desoxy-5-C-[(8R)-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8' pentaoxo-1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[gjisoquinoline-8,2' cyclopenta[b]-naphthalene]-3-yljpentitol (3) Twelve (12.0) mg (19.8 pmol) fredericamycin tetrol (2) are dissolved in 1.5 mL absolute pyridine under nitrogen atmosphere. The solution is gassed for 30 min with argon at 0' C. Under the argon atmosphere, 5.94 mL of a 0.01 N KOH solution are added at once at 0* C. The reaction solution immediately turns turquoise. The reaction mixture is stirred for another 1 hour, and subsequently is frozen and lyophilized. Yield: 13.2 mg (100% of the theoretical value); deep blue crystal mass. Example 3 55 (8S)-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopenta[b]-naphthalene]-3 carbaldehyde (4) 1.) Fifty (50) mg (82.3 imol) tetrahydroxy fredericamycin (tetrol (2)) are dissolved in 4 mL DMF. Under vigorous stirring, an aqueous sodium iodate solution (300 mg NaIO 4 in I mL water) is added dropwise within one hour. After I h stirring at room temperature, 2 drops of trifluoracetic acid are added. After stirring for another 30 min, the reaction solution is diluted with 3 ml DMF, and 150 mg NaIO 4 dissolved in 0.5 ml water are added. After another hour, 100 mL water are added. The supernatant over the precipitate is sucked off, and dryed in HV. Dark red crystal powder. Yield: 41 mg (100 % of the theoretical value). M/e = 501.3, UVma: 504.0 nm. 2.) One hundred and nine (109) mg (179 pmol) fredericamycin tetrol (2) are dissolved in 8 mL pyridine. 180 iL water are added. To the reaction mixture, 450 mg (1.08 mmol, 6 eq.) (polystryrylmethyl)trimethylammonium periodate resin are added. Then the mixture is stirred for 12 h at RT. The resin is filtered off; washing and concentrating until dry. Dark red residue. Yield: 89.9 mg (100 % of the theoretical value). M/e = 501.3, UVma: 504.0 nm. Example 4 1-[2-Oxo-2-((2E)-2-{[(8S)-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo 1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopenta[b] naphthalenel-3-yllmethylene} ethyl]-dimethylamino trifluoroacetate (118) Twenty (20) mg (39.9 pmol) fredericamycin aldehyde (4) are dissolved under argon in 1.5 mL absolute DMF. Addition of 9.1 mg (47.9 pmol, 1.2 eq.) acetylhydrazide dimethylammoniumchloride (Girard reagent D) and 20 mg polyvinylpyridine (2% DVB). The mixture is stirred for 2.5 h. Then, 27 mg (80 pmol, 2.0 eq.) aldehyde Wang resin (coating: 3.0 mmol/g) are added and stirred for another I h. Then, the resin is filtered, and washed 3x with DMF. Concentration in high vacuum. The residue is dissolved in I ml trifluoracetic acid, and concentrated after 10 min until dry.
56 Red solid; Yield: 28.5 mg (100%); ES+: M/e = 601.3, UVm: 504.0 nm. Example 5 1-[2-Oxo-2-((2E)-2-{[(8S)-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo 1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[gjisoquinoline-8,2'-cyclopentalb] naphthalene]-3-yllmethylene)hydrazino)-ethyl]pyridinium chloride (119) Fifteen (15) mg (29.9 imol) fredericamycin aldehyde (4) are dissolved in 3 mL DMF. At room temperature 7.5 mg (40.0 ptmol) acethydrazinopyridinium chloride (Girard reagent P) dissolved in 75 pL water are added. The reaction mixture is stirred for 1.5 h at room temperature, and the course of the reaction is monitored by HPLC. When finished, acetic acid ethyl ester is added to the reaction mixture, until a precipitation occurs. After the crystallization is finished, the red solid is sucked off. Yield: 9.1 mg (44% of the theoretical value). M/e = 635.2; ma: 486.0. Example 6 (8S)-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospirolcyclopenta[g]isoquinoline-8,2'-cyclopenta[b]-naphthalene]-3 carbaldehyde oxime (122) Ten (10) mg (19.4 imol) fredericamycin aldehyde (4) are dissolved in 2 mL DMF. After addition of 3.1 mg (44.6 pmol) hydroxylammonium chloride, 3.2 ptl pyridine are added. Stirring for 2 h at room temperature. The reaction mixture is added to 50 ml water and extracted 3 times with ethyl acetate. After drying and concentration, a deep red amorphous crystal powder was left (HPLC clean). Yield: 7.4 mg (72% of the theoretical value). ES~: M/e = 516.1; Xma: 500.0 nm. Example 7 (8S)-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro cyclopenta[g]isoquinoline-8,2'-cyclopenta [b]-naphthalene]-3 carbaldehyde-O-methyloxime (8) 57 Ten (10) mg (19.4 ptmol) fredericamycin aldehyde (4) are dissolved in 2 mL DMF. After addition of 3.4 mg (40.7 imol) O-methylhydroxylammonium chloride and 3.2 ptl pyridine, the reaction mixture is stirred for 2 h at room temperature. Then, it is added to 100 ml water, and the supernatant is sucked off from the red precipitate (HPLC clean). Yield: 7.6 mg (71% of the theoretical value). ES*: M/e = 531.2; kmax: 500.0. Example 8 (8S)-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopenta[b]-naphthalene]-3 carbaldehyde-O-benzyloxime (9) Ten (10) mg (19.4 pmol) fredericamycin aldehyde (4) are dissolved in 2 mL DMF. After addition of 6.4 mg (43.2 imol) 0-benzylhydroxylammonium chloride and 3.2 Vl pyridine, the reaction mixture is stirred for 2 h at room temperature. Then, it is added to 50 ml water, and the supernatant is sucked off from the red precipitate (HPLC clean). Yield: 6.8 mg (57% of the theoretical value). ES*: M/e = 607.2; m 504.0 nm. Example 9 1-0-({(1E)-[(8S)-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta [g]isoquinoline-8,2'-cyclopenta [b]-naphthalene]-3 yllmethylene}amino)- -- D-glucopyranose (10) Two (2.0) mg (4.0 imol) fredericamycin aldehyde (4) are dissolved in 150 pL DMF, and 0.86 mg (4.4 pmol) p-aminoxy-D-glucopyranose is added. The mixture is stirred for 24 h at room temperature, and 5 mg (15.0 jimol) aldehyde Wang resin (coating: 3.0 mmol/g) is added. After stirring for another 3 h, the resin is filtered off, washed with DMF, and the filtrate is concentrated in high vacuum until dry. Yield: 2.7 mg (99% of the theoretical value). red powder; ES-: M/e = 678.1; ?ma: 504.0 nm.
58 Example 10 (8S)-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[glisoquinoline-8,2'-cyclopenta[b]-naphthalene] 1,1',3',5',8'(2H)-pentone (11) Thirty (30) mg (49.4 pimol) tetrahydroxy fredericamycin (2) were dissolved in 2 mL pyridine. Twenty (20) mg (93.0 ptmol) sodium metaperiodate dissolved in 0.3 ml water are added. After stirring for 4 h, 10 mg (260 pmol) sodium borohydride are added. After 12 h, concentration until dry, and the residue is separated by preparative HPLC. Yield: 2.6 mg (13% of the theoretical value) red powder. ES~: M/e = 503.2; Xma: 504.0 nm. Example 11 (8S)-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro cyclopenta [g] isoquinoline-8,2'-cyclopenta [bI-naphthalene]-3 carboxylic acid (12) Fifteen (15) mg (29.9 pmol) fredericamycin aldehyde (4) are dissolved in 1 mL dichloromethane and 0.5 ml t-butanol. Addition of 250 pl 2,4-dimethylbutene. Under stirring at room temperature, a solution of 6.0 mg (53.1 pmol) sodium chlorite (80%) and 5.1 mg sodium hydrogenphosphate in 250 ptl water are added dropwise. After 2.5 h, again a solution of 10.0 mg (88.5 tmol) sodium chlorite and 5 mg sodium dihydrogenphosphate in 200 pil water are added. After altogether 4 h, it is put on water, and extracted with ethyl acetate. The raw mixture was purified by preparative HPLC (RP18, acetonitrile-water-acetic acid). Red amorphous powder. Yield: 68.3 mg (53.5% of the theoretical value). E~: M/e = 516.1; Xma: 504.0 nm. Example 12 59 Potassium(8S)-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro [cyclopenta [g]isoquinoline-8,2'-cyclopenta [b]-naphthalene]-3 carboxylate (13) 6.9 mg (13.3 ptmol) Fredericamycin carboxylic acid (12) are dissolved in 5 mL DMF under nitrogen. At room temperature and under oxygen exclusion and vigorous stirring, 1.27 mL (12.7 imol) of an aqueous 0.01 N KOH solution is added dropwise. It is stirred for 15 minutes at room temperature, and concentrated in high vacuum until dry. Yield: 7.40 mg (100% of the theoretical value). E~: M/e = 516.1; Xnax: 504.0 nm. Example 13 (8S)-5-bromo-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopenta[b]-naphthalene] 1,1',3',5',8'(2H)-pentone (14) Twenty (20) mg (37.1 pmol) fredericamycin (1) were dissolved in 250 il DMF, and then 6. 3 mg (35.3 ptmol) N-bromosuccinimide in 250 pd DMF were added within one hour at 0* C. The reaction was stirred in a slowly thawing ice bath over night. Then, the DMF is removed in high vacuum, and the residue is purified by preparative HPLC. Yield: 7 mg (32% of the theoretical value) red crystal mass. M/e = 616.1/618.1; Xm: 486.0 nm. Example 14 (8S)-5-iodo-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro [cyclopenta[g]isoquinoline-8,2'-cyclopenta [b]-naphthalene] 1,1',3',5',8'(2H)-pentone (15) Eighty four (84) mg (158 pmol) fredericamycin (1) were dissolved in 1.0 pl DMF, and then 33.0 mg (150.0 pmol) N-iodosuccinimide in 500 ptl DMF were added within one hour at 0' C. The reaction was stirred in a slowly thawing ice bath over night. Then, the DMF is 60 removed in high vacuum, and the residue (120 mg (14) with a content of 80%) is purified by preparative HPLC (gradient CH 3 CN 50-90% over 16 min.) Yield: 18 mg (17% of the theoretical value) red crystal mass. M/e = 665.0; Xna: 484.0 nim. Example 15 Methyl-2-{[(benzyloxy)carbonyli amino}-3-[(8S)-4',9,9'-trihydroxy-6'-methoxy 1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[glisoquinoline- 8
,
2
'
cyclopenta [b] -naphthalene] -3-yl] acrylate (23) Sixty six (66) mg (200 pimol) Z-a-phosphonoglycine trimethylester are dissolved under argon in 1 mL absolute pyridine, and 25 iL 1,1,3,3-tetramethylguanidine are added at 0* C. After 40 min. 20 mg (40 pmol) fredericamycin aldehyde (4) is added at 0* C. After 15 min. 20 ml 1 M acetic acid is added, and the mixture is extracted 3 x with acetic acid. The raw product is purified by preparative HPLC (RP 18, acetonitrile-water). Yield: 10.0 mg (36% of the theoretical value). M/e = 706.4; ma,: 492.0 rim. Example 16 (8S)-9-hydroxy-4',6',9'-trimethoxy-2-methyl-3-[(1E,3E)-penta-1,3-dienyl]-6,7 dihydrospiro [cyclopenta[g]isoquinoline-8,2'-cyclopenta [b]-naphthalene] 1,1',3',5',8'(2H)-pentone (24) Ten (10) mg (15 pmol) fredericamycin (1) were dissolved under protective gas in 4 ml absolute DMF. At RT, 400 il (4311 pmol) methyliodide and 81 mg powdered potassium carbonate are added. The reactions mixture is then stirred at RT for 20 h, and is then transferred onto water. Extraction with ethyl acetate, and purification of the residue by separating chromatography on chloroform/methanol 30/1. Yield: 4 mg (37% of the theoretical value). Yellow residue. We = 582.3; Xma: 368.0 n. Example 17 61 Fredericamycin A 1:2 complex with a-cyclodextrin (22) Ten (10) mg fredericamycin (0.025 mMol) are added to a solution of 50 mg x-cyclodextrin (0.050 mMol) in 500 ptl dimethylsulfoxide. The solution is then diluted with 5 ml water. A stock solution prepared in such way can be diluted as desired with water. Xma = 504.0 nm. Example 18 4',9,9'-Trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[gJisoquinoline-8,2'-cyclopenta[b]-naphthalene]--3 carbaldehyde(4-methylpiperazine-1-yl)hydrazone (111) Five (5) mg (9.42 pmol) fredericamycin aldehyde (4) are dissolved in 500 1 DMF and 25 p1 trifluoracetic acid. At room temperature, 1.30 mg (11.3 pmol) 1-amino-4-methyl piperazine is added. After stirring for 4.5 h at room temperature, 1 equivalent each of Wang aldehyde resin and sulfonohydrazide resin is added and stirred for 2 h. Filtration and concentration of the reaction solution at high vacuum. Red powder. Yield: 5.4 mg (91% of the theoretical value). M/e = 599 (M+H)*; .ma: 504.0 nm. Example 19 4',9,9'-Trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopenta[b]-naphthalene]-3 carbaldehyde-4,5-dihydro-1H-imidazole-2-yl-hydrazone (123) Five (5.00) mg (9.42 pmol) fredericamycin aldehyde (4) are dissolved in 500 pl DMF and 25 p1 trifluoracetic acid. At room temperature, 2.05 mg (11.3 pmol) 2-hydrazino-2 imidazolin hydrobromide is added. After stirring for 4.5 h at room temperature, 1 equivalent each of Wang aldehyde resin and sulfonohydrazide resin are added and stirred for 2 h.
62 Separation of the resin by filtration and concentration of the reaction solution at high vacuum. Red powder. Yield: 3.9 mg (67% of the theoretical value). M/e = 584 (M+H)*; Xmax: 504.0 nm. Example 20 4',9,9'-Trihydroxy-6'-methoxy-3-{(E)-[(4-oxo-2-thioxo-1,3-thiazolidin-3 yl)imino]methyl}-6,7-dihydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopenta [b] naphthalene]-1,1',3',5',8'(2H)-pentone (123) Five (5.00) mg (9.42 pmol) fredericamycin aldehyde (4) are dissolved in 500 pl DMF and 25 jil trifluoracetic acid. At room temperature, 1.67 mg (11.3 ptmol) 2N-aminorhodanide are added. After stirring for 4.5 h at room temperature, I equivalent each of Wang aldehyde resin and sulfonohydrazide resin are added and stirred for 2 h. Filtration and concentration of the reaction solution. Red powder. Yield: 4.1 mg (65% of the theoretical value). M/e = 599 (M+H)*; Xma: 504.0 nm. Example 21 4',9,9'-Trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[glisoquinoline-8,2'-cyclopenta[b]-naphthalene]-3 carbaldehyde-O-(2-morpholine-4-ylethyl)oxime (27) Five (5.00) mg (9.42 pimol) fredericamycin aldehyde (4) are dissolved in 500 pl DMF and 25 pl trifluoracetic acid. At room temperature, 2.47 mg (11.3 pmol) N (aminoxyethyl)morpholine dihydrochloride is added. After stirring for 4.5 h at room temperature, I equivalent of Wang aldehyde resin (3.1 mg, 9.4 pimol, coating: 3.0 mmol/g) as well as I equivalent sulfonohydrazide resin (6.1 mg, 9.4 mmol, 1.5 mmol) are added and stirred for 2 h. Filtration and concentration of the reaction solution.
63 Red powder. Yield: 6.1 mg (98% of the theoretical value). M/e = 630 (M+H)*; Xma,: 504.0 nm. Example 22 (8S)-5-chloro-4',6',9'-trimethoxy-2-methoxy-3-[(1E,3E)-penta-1,3-dienyl]-6,7 dihydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopenta[b]-naphthalene] 1,1',3',5',8'(2H)-pentone (34) Three hundred (300) mg (556.6 pmol) fredericamycin (1) are dissolved under argon in 10 pl DMF, and then 75.0 mg (556.6 pmol) N-chlorosuccinimide are added. The reaction is stirred for 5 h at 40* C. The reaction mixture is then added to 400 ml methanol/water 1:1, and the red precipitate is sucked off and dried at high vacuum. Yield: 305 mg (96% of the theoretical value) red crystal mass. M/e = 573/575; Am,: 504.0 nm. Example 23 (8S)-5-fluoro-4',9,9'-trihydroxy-6'-methoxy-3-[(1E,3E)-penta-1,3-dienyl]-6,7 dihydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopenta[b]-naphthalene] 1,1',3',5',8'(2H)-pentone (35) Fifty (50) mg (92.8 pmol) fredericamycin (1) are dissolved in 5 ml DMF under argon, and then 33.0 mg (93.5 imol) 1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) Selectfluor @ is added. The reaction is stirred for 24 h at room temperature. The reaction mixture is then added to 200 ml water, and is extracted with ethyl acetate. The concentrated raw product is purified by preparative HPLC (RP18, acetonitrile-water-acetic acid). Yield: 7.1 mg (14% of the theoretical value) red crystal mass. M/e = 557; Xmax: 504.0 nm. Example 24 64 1-Desoxy-5-C- [(8R)-5-chloro-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo 1,1',2,3',5',6,7,8'-octahydrospiro [cyclopenta [g]isoquinoline-8,2'-cyclopenta [b] naphthalene]-3-yll-pentitol (36) Hundred twenty (120) mg (209 mmol) chlorofredericamycin (34) are dissolved in 25.0 ml dichloromethane. After addition of 3.6 ml methanol and 0.8 ml water, 197 mg (1.46 mmol) N-methylmorpholine-N-oxide is added. Under vigorous stirring, 0.12 ml of a 2.5% solution of osmium(IV)oxide in t-butanol is added dropwise. After stirring for 27 hours, the reaction is complete, according to HPLC monitoring (RP18, acetonitrile-water (0.2% acetic acid)). The reaction mixture is added to 200 ml water under vigorous stirring, and the dark red solid is sucked off. Drying in HV. Yield: 101 mg (75% of the theoretical value) dark red powder. M/e = 641/643; ?ma,: 504.0. Example 25 (8S)-4',9,9'-trihydroxy-5-bromo-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopentalgisoquinoline-8,2'-cyclopenta[b]-naphthalene]-3 carbaldehyde (37) Hundred (100) mg (200 pmol) fredericamycin aldehyde (4) are dissolved under argon in 5 ml DMF. Then, 200 pl of a IM bromine solution in DMF is added. After stirring for 1.5 h at RT, another 20 pl bromine solution are added. According to HPLC monitoring, the reaction mixture is complete after 3.5 h. Add to 150 ml water, and shake out with dichloromethane. Yield: 96 mg (83% of the theoretical value) dark red powder. M/e = 579/581; Xmax: 504.0. Example 26 1,2,3,4-Tetrahydro-5-bromo-4',9,9'-trihydroxy-6'-methoxy-3-[(1E,3E)-penta-1,3 dienyl] -6,7-dihydrospiro [cyclopenta [g] isoquinoline-8,2'-cyclopenta [b] -naphthalene] 1,1',3',5',8'(2H)-pentone (26) 65 Eight (8.0) mg (0.0128 mmol) 1,2,3,4-tetrahydrofredericamycin (25) are dissolved in 1 ml absolute DMF under nitrogen. Then a solution of 2.3 mg (0.0128 mmol) bromine in 0.25 ml DMF is added dropwise to the solution. Stirring at room temperature over 24 h. The reaction mixture is concentrated to half volume in high vacuum, and is then transferred onto 100 ml water. The supernatant is sucked off from the precipitate and dried in a vacuum. Red crystal powder 8.1 mg (88% of the theoretical value) m/e = 621/623; ,ma: 499 nm. Example 27 (8S)-4',9,9'-trihydroxy-6'-benzylamino-3-[(1E,3E)-penta-1,3-dienyl]-6,7 dihydrospiro[cyclopenta[glisoquinoline-8,2'-cyclopenta[b]-naphthalene] 1,1',3',5',8'(2H)-pentone Twenty (20) mg (37.1 pmol) fredericamycin are dissolved in I ml DMF under argon, then 4.76 mg (44.50 pmol) benzylamine are added at room temperature. According to HPLC (RP 18, acetonitrile/water), a homogenous new product has formed after 3 h. The reaction mixture is concentrated at high vacuum until dry. Red crystal mass; Yield: 23 mg (100% of the theoretical value) M/e = 615.3 (M+H); Xma: 492 nm. Example 28 (8S)-5-chloro-4',9,9'-trihydroxy-6'-benzylamino-3-[(1E,3E)-penta-1,3-dienyl]-6,7 dihydrospiro [cyclopenta[g] isoquinoline-8,2'-cyclopenta[b]-naphthalene] 1,1',3',5',8'(2H)-pentone Five (5.0) mg (8.71 pmol) 5-chlorofredericamycin are dissolved in 1 ml DMF under argon, then 1.12 mg (10.45 pmol) benzylamine are added at room temperature. After 29 h, the reaction mixture is concentrated at high vacuum until dry. Red crystal mass; Yield: 5 mg (89% of the theoretical value) M/e = 649.1 (M+H); %.max: 492 nm.
66 Example 28 (Translator: 28a) (8S)-4',9,9'-trihydroxy-6'-ethanolamino-3-[(1E,3E)-penta-1,3-dienyl]- 6
,
7 dihydrospiro[cyclopenta[gJisoquinoline-8,2'-cyclopenta[b]-naphthalenel 1,1',3',5',8'(2H)-pentone Ten (10) mg (18.6 pmol) fredericamycin are dissolved in 1 ml DMF under argon, then 1.36 mg (22.3 pmol) ethanolamine are added at room temperature. According to HPLC (RP18, acetonitrile/water), a homogenous new product has formed after 3 h. The reaction mixture is concentrated at high vacuum until dry. Red crystal mass; Yield: 9 mg (85% of the theoretical value) M/e = 569.3 (M+H); knm: 500 nm. Example 29 (8S)-4',9,9'-trihydroxy-6'-(4-piperidylmethylamino)-3-[(1E,3E)-penta-1,3-dienyl]-6,7 dihydrospiro [cyclopenta [g]isoquinoline-8,2'-cyclopenta [b]-naphthalene] 1,1',3',5',8'(2H)-pentone Ten (10) mg (18.6 ptmol) fredericamycin are dissolved in 1 ml DMF under argon, then 2.7 1d (22.3 ptmol) 4-aminomethylpiperidine are added at room temperature. The reaction mixture is concentrated at high vacuum until dry after 24 h. Red crystal mass; Yield: 11 mg (99% of the theoretical value) M/e = 622.3 (M+H); Xma: 492 nm. Examples 100 - 142 The compounds 100 - 142 can be generated analogously to examples 7, 8, 9, 10, 18, 19 and 20: Example 100 67 4',9,9'-Trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro [cyclopenta [g]isoquinoline-8,2'-cyclopenta[b]-naphthalene]-3 carbaldehydepyridine-2-yl-hydrazone (100) Yield: (95% of the theoretical value) MS: M/e = 593.1; Xma: 500.0 nm. Example 101 4',9,9'-Trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[gisoquinoline-8,2'-cyclopentatbl-naphthalenel-3 carbaldehyde 14-(trifluoromethyl)pyrimidine-2-yllhydrazone (101) Yield: (95% of the theoretical value) MS: M/e = 562.1; Xma: 500.0 nm. Example 102 N'-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[glisoquinoline-8,2'-cyclopentalb]-naphthalene]-3 yl)methylene] pyridyl-3-carbohydrazine (102) Yield: (95% of the theoretical value) MS: M/e = 621.1; Xm.: 492.0 nm. Example 103 N'-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro cyclopenta[g]isoquinoline-8,2'-cyclopenta [b]-naphthalene]-3 yl)methylenelisonicotinohydrazine (103) Yield: (95% of the theoretical value) MS: M/e = 621.1; 2ma: 500.0 rnm. Example 104 4',9,9'-Trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospirocyclopenta[g] isoquinoline-8,2'-cyclopenta[b]-naphthalene]-3 carbaldehyde-1,2,4-triazole-4-ylhydrazone (104) Yield: (80% of the theoretical value) MS: M/e = 568.1; Xma: 500.0 nm. Example 105 4',9,9'-Trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[glisoquinoline-8,2'-cyclopenta[b]-naphthalene]-3 carbaldehyde-4,5-dihydro-1H-imidazole-2ylhydrazone (105) 68 Yield: (95% of the theoretical value) MS: M/e = 584.1; Xma: 492.0 nm. Example 106 N'-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopentalg]isoquinoline-8,2'-cyclopenta[b]-naphthalene]-3 yl)methylene] -2-furohydrazine (106) Yield: (95% of the theoretical value) MS: M/e = 610.0; Xma: 492.0 nm. Example 107 4-Amino-N'-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo 1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[gisoquinoline-8,2'-cyclopenta[b] naphthalene]-3-yl)methylene]benzohydrazine (107) Yield: (95% of the theoretical value) MS: M/e = 635.1; Xmax: 492.0 nm. Example 108 4',9,9'-Trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro [cyclopenta [g] isoquinoline-8,2'-cyclopenta [b] -naphthalene]-3 carbaldehydethiosemicarbazone (108) Yield: (95% of the theoretical value) MS: M/e = 558.0; Xma.: 492.0 nm. Example 109 N'-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospirolcyclopenta[g]isoquinoline-8,2'-cyclopenta[b]-naphthalene]-3 yl)methylene]thiophene-2-carbohydrazine (109) Yield: (95% of the theoretical value) MS: M/e = 626.0; Xma.: 492.0 nm. Example 110 2-(1H-indole-3-yl)-N'-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo 1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[gisoquinoline-8,2'-cyclopenta[b] naphthalene]-3-yl)methylenelacetohydrazine (110) Yield: (95% of the theoretical value) MS: M/e = 673.1; Ama: 492.0 rm. Example 111 69 4',9,9'-Trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro [cyclopenta[g]isoquinoline-8,2'-cyclopenta [b]-naphthalene]-3 carbaldehyde(4-methylpiperazine-1-yl)hydrazone (111) Yield: (95% of the theoretical value) MS: M/e = 599.1; Xmax: 492.0 nm. Example 112 2-Oxo-2-{(2E)-2-[(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo 1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[gJisoquinoline-8,2'-cyclopenta[b] naphthalene]-3-yl)methylene]-hydrazino)acetamide (112) Yield: (95% of the theoretical value) MS: M/e = 587.1; ax,: 492.0 nm. Example 113 4',9,9'-Trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopenta[b]-naphthalene] 1,1',3',5',8'(2H)-pentone (113) Yield: (95% of the theoretical value) MS: M/e = 632.0; Lmax: 500.0 nm. Example 114 {(2E)-2-[(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[glisoquinoline-8,2'-cyclopentafb]-naphthalene]-3 yl)methylene]-hydrazino)acetonitrile (114) Yield: (95% of the theoretical value) MS: M/e = 583.1; ?max: 492.0 nm. Example 115 2-Amino-N'-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo 1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopenta[b] naphthalene]-3-yl)methylene]benzohydrazine (115) Yield: (95% of the theoretical value) MS: M/e = 635.1; kmax: 492.0 nm. Example 116 4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahyd rospiro [cyclopenta [g] isoquinoline-8,2'-cyclopenta [b] -naphthalene] -3 carbaldehyde 0-[2-morpholine-4-yl-ethyl]oxime (116) 70 Yield: (85% of the theoretical value) MS: M/e = 630.1; 2ma: 492.0 nrn. Example 117 (2E)-2-[(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo--1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[gisoquinoline-8,2'-cyclopenta[b]-naphthalenel-3 yl)methylene]hydrazinecarboximidamide (117) Yield: (95% of the theoretical value) MS: M/e = 558.1; Ama: 500.0 nm. Example 118 2-(Dimethylamino)-N'-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo 1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopentalb] naphthalene]-3-yl)methylene] acetohydrazine (118) Yield: (85% of the theoretical value) MS: M/e = 601.1; Xma.: 492.0 nm. Example 119 1-[2-Oxo-2-((2E)-2-{[(8S)-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo 1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[gJisoquinoline-8,2'-cyclopenta[b] naphthalene]-3-yli)methylene) hydrazino)ethyl] pyridinium chloride (119) Yield: (85% of the theoretical value) MS: M/e = 635.1; ma: 492.0 nm. Example 120 (8S)-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta [g] isoquinoline-8,2'-cyclopenta [b]-naphthalene]-3 carbaldehyde O-methyloxime (120) Yield: (90% of the theoretical value) MS: M/e = 531.1; Xma,: 492.0 nm. Example 121 4',9,9'-Trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopenta[b]-naphthalenel-3 carbaldehyde O-benzyloxime (121) Yield: (95% of the theoretical value) MS: M/e = 607.1; km,: 492.0 nm. Example 122 71 4',9,9'-Trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospirolcyclopenta [g] isoquinoline-8,2'-cyclopenta [b]-naphthalene]-3 carbaldehyde oxime (122) Yield: (95% of the theoretical value) MS: M/e = 517.1; ma: 482.0 nm. Example 123 1-0-({(1E)-[(8S)-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospirolcyclopenta[glisoquinoline-8,2'-cyclopenta[b]-naphthalene]-3 yl)methylene) amino)- -D-glucopyranose (123) Yield: (95% of the theoretical value) MS: M/e = 679.1; Xma: 500.0 nm. Example 124 4',9,9'-Trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro [cyclopenta [g] isoquinoline-8,2'-cyclopenta [b]-naphthalene] -3 carbaldehyde-phenylsemicarbazone (124) Yield: (95% of the theoretical value) MS: M/e = 635.1; )mz: 492.0 nm. Example 125 4',9,9'-Trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[gisoquinoline-8,2'-cyclopenta[b]-naphthalenel-3 carbaldehydesemicarbazone (125) Yield: (95% of the theoretical value) MS: M/e = 559.1; kma: 492.0 nm. Example 126 2-Piperidino-4-yl-N'-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo 1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[gisoquinoline-8,2'-cyclopenta[b] naphthalene] -3-yl)methylenel acetohydrazide (126) Yield: (95% of the theoretical value) MS: M/e = 641.1; km.: 492.0 nm. Example 127 4',9,9'-Trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[gisoquinoline-8,2'-cyclopenta[b]-naphthalene]-3 carbaldehyde 0-(3-chlorobenzyl)oxime (127) 72 Yield: (95% of the theoretical value) MS: M/e = 641.1; %.max: 492.0 nm. Example 128 N'-[(lE)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro cyclopenta[gjisoquinoline-8,2'-cyclopenta[b]-naphthalene]-3 yl)m ethylene] -(2-methyl-1,3-thiazole-4yl)carbohydrazide (128) Yield: (95% of the theoretical value) MS: M/e = 641.1; Amax: 492.0 nn. Example 129 2-(1H-imidazole-1-yl)-N'-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo 1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[glisoquinoline-8,2'-cyclopentalb] naphthalene]-3-yl)methylenel acetohydrazide (129) Yield: (90% of the theoretical value) MS: M/e = 624.1; %ax: 500.0 nm. Example 130 2-(Acetylamino)-N'-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo 1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[glisoquinoline-8,2'-cyclopenta[b] naphthalene]-3-yl)methylenejacetohydrazide (130) Yield: (95% of the theoretical value) MS: M/e = 615.1; Xmax: 492.0 nm. Example 131 2-(4-Methylpiperazine-1-yl)-N'-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8' pentaoxo-1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[glisoquinoline-8,2' cyclopenta[b]-naphthalenel-3-yl)methylenelacetohydrazide (131) Yield: (50% of the theoretical value) MS: M/e = 656.1; Xmax: 492.0 nm. Example 132 2-Morpholine-4-yl-A'-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo 1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopenta[b] naphthalene]-3-yl)methylenejacetohydrazide (132) Yield: (60% of the theoretical value) MS: M/e = 643.1; Xnmax: 492.0 nm. Example 133 73 2-(Methylamino)-A-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo 1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta [glisoquinoline-8,2'-cyclopenta[b] naphthalene]-3-yl)methylene]acetohydrazide (133) Yield: (70% of the theoretical value) MS: M/e = 587.1; ma: 492.0 nm. Example 134 2-[Isopropyl(methyl)amino]-N-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8' pentaoxo-1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[giisoquinoline-8,2' cyclopenta [b]-naphthalene]-3-yl)methylenel acetohydrazide (134) Yield: (70% of the theoretical value) MS: M/e = 629.1; Xma: 492.0 rnm. Example 135 4',9,9'-Trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[gisoquinoline-8,2'-cyclopenta[b]-naphthalenel-3 carbaldehyde 0-12-(dimethylamino)ethyl]oxime (127) Yield: (90% of the theoretical value) MS: M/e = 588.1; kma: 492.0 nm. Example 136 4',9,9'-Trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta [g]isoquinoline-8,2'-cyclopenta[b]-naphthalene]-3 carbaldehyde 0-[3-(4-(3-chlorophenyl)-piperazine-1-yl)propylloxime (136) Yield: (85% of the theoretical value) MS: M/e =753.1; Xma: 492.0 nm. Example 137 4',9,9'-Trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[gisoquinoline-8,2'-cyclopentab]-naphthalene-3 carbaldehyde O-[3-(dimethylamino)propyl]oxime (137) Yield: (70% of the theoretical value) MS: M/e = 602.1; X.ma: 492.0 nm. Example 138 (8S)-5-chloro-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[gjisoquinoline-8,2'-cyclopentajb]-naphthalene]-3 carbaldehydepyridine-2-yl-hydrazone (138) 74 Yield: (95% of the theoretical value) MS: M/e = 627.0; , 1 a: 500.0 nm. Example 139 (8S)-5-chloro-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta [g]isoquinoline-8,2'-cyclopenta [b]-naphthalene]-3 carbaldehyde [4-(trifluoromethyl)pyrimidine-2-ylhydrazone (139) Yield: (95% of the theoretical value) MS: M/e = 696.0; 2ma: 500.0 n. Example 140 (8S)-5-chloro-N'-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo 1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopenta[b] naphthalene]-3-yl)methylene]pyridyl-3-carbohydrazine (140) Yield: (95% of the theoretical value) MS: M/e = 655.0; 2ima: 500.0 nm. Example 141 (8S)-5-chloro-N'-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo 1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopenta[b] naphthalene]-3-yl)methylene] isonicotinohydrazide (141) Yield: (95% of the theoretical value) MS: M/e = 655.0; knm: 500.0 nm. Example 142 (8S)-5-chloro-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopenta[b]-naphthalenel-3 carbaldehyde-1,2,4-triazole-4-ylhydrazone (142) Yield: (90% of the theoretical value) MS: M/e = 602.0; kma: 500.0 un. Example 143 (8S)-5-chloro-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[glisoquinoline-8,2'-cyclopenta[b]-naphthalenel-3 carbaldehyde-4,5-dihydro-1H-imidazole-2-ylhydrazone (143) Yield: (95% of the theoretical value) MS: M/e = 618.0; Xmax: 500.0 nm. Example 144 75 (8S)-5-chloro-N'-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo 1,1',2,3',5',6,7,8'-octahydrospiro [cyclopenta[g] isoquinoline-8,2'-cyclopenta [b] naphthalene]-3-yl)methylene]-2-furohydrazide (144) Yield: (95% of the theoretical value) MS: M/e = 644.0; Xma: 500.0 nm. Example 145 (8S)-5-chloro-4-amino-N'-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo 1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[gjisoquinoline-8,2'-cyclopenta[bl naphthalene]-3-yl)methylene]-benzohydrazide (145) Yield: (95% of the theoretical value) MS: M/e = 669.0; Xma: 500.0 nfm. Example 146 (8S)-5-chloro-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[giisoquinoline-8,2'-cyclopenta[b]-naphthalene]-3 carbaldehydethiosemicarbazone (146) Yield: (95% of the theoretical value) MS: M/e = 609.0; Xmax: 500.0 nm. Example 147 (8S)-5-chloro-N'-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo 1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopenta[b] naphthalene] -3-yl)methylenelthiophene-2-carbohyd razide (147) Yield: (95% of the theoretical value) MS: M/e = 660.0; Xmax: 500.0 nm. Example 148 (8S)-5-chloro-2-(1H-indole-3-yl)-N'-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8' pentaoxo-1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[gisoquinoline-8,2' cyclopenta[b]-naphthalene]-3-yl)methylenelacetohydrazide (148) Yield: (95% of the theoretical value) MS: M/e = 707.1; ?max: 500.0 nm. Example 149 (8S)-5-chloro-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta [g]isoquinoline-8,2'-cyclopenta[b]-naphthalene]-3 carbaldehyde(4-methylpiperazine-1-yl)hydrazone (149) 76 Yield: (95% of the theoretical value) MS: M/e = 633.1; Ama: 500.0 nm. Example 150 (8S)-5-chloro-2-oxo-2-{(2E)-2-[4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo 1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[glisoquinoline-8,2'-cyclopenta[b] naphthalene]-3-yl)methylene]hydrazino)acetamide (150) Yield: (95% of the theoretical value) MS: M/e = 621.0; Xma: 500.0 nm. Example 151 (8S)-5-chloro-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro [cyclopenta [g] isoquinoline-8,2'-cyclopenta [b] -naphthalene] 1,1',3',5',8'(2H)-pentone (151) Yield: (95% of the theoretical value) MS: M/e = 665.3; Xma: 500.0 nm. Example 152 (8S)-5-chloro-{(2E)-2-[4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo 1,1',2,3',5',6,7,8'-octahydrospirotcyclopenta[g]isoquinoline-8,2'-cyclopenta b] naphthalene] -3-yl)methylenej hydrazino) acetonitrile (152) Yield: (95% of the theoretical value) MS: M/e = 617.1; ?m: 500.0 run. Example 153 (8S)-5-chloro-2-amino-N'-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo 1,1',2,3',5',6,7,8'-octahydrospirolcyclopenta[gisoquinoline-8,2'-cyclopenta[b] naphthalene]-3-yl)methylenebenzohydrazide (153) Yield: (95% of the theoretical value) MS: M/e = 669.1; Xma: 500.0 nm. Example 154 (8S)-5-chloro-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopenta[b]-naphthalene]-3 carbaldehyde O-[2-morpholine-4-yl-ethyl)oxime (154) Yield: (95% of the theoretical value) MS: M/e = 664.1; Xma: 500.0 nm. Example 155 77 (8S)-5-chloro-(2E)-2-[(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo 1,1',2,3',5',6,7,8'-octahydrospiro [cyclopenta [g]isoquinoline-8,2'-cyclopenta [bl naphthalene]-3-yl)methylene]hydrazinecarboximidamide (155) Yield: (95% of the theoretical value) MS: M/e = 592.1; Xma: 500.0 nm. Example 156 (8S)-5-chloro-2-(dimethylamino)-N'-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8' pentaoxo-1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[glisoquinoline-8,2' cyclopenta[b]-naphthalene]-3-yl)methylene]acetohydrazide (156) Yield: (95% of the theoretical value) MS: M/e = 635.1; Xm.: 500.0 nm. Example 157 (8S)-5-chloro-1-[2-oxo-2-((2E)-2-{[(8S)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8' pentaoxo-1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[gjisoquinoline-8,2' cyclopenta [b]-naphthalene]-3-yl)methylene] hydrazino)ethylj pyridinium chloride (157) Yield: (95% of the theoretical value) MS: M/e = 669.1; kma: 500.0 nm. Example 158 (8S)-5-chloro-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro [cyclopenta [g] isoquinoline-8,2'-cyclopenta [b]-naphthalene]-3 carbaldehyde-O-methyloxime (158) Yield: (95% of the theoretical value) MS: M/e = 565.0; ?ma: 500.0 nm. Example 159 (8S)-5-chloro-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[giisoquinoline-8,2'-cyclopenta[b]-naphthalene]-3 carbaldehyde-O-benzyloxime (159) Yield: (95% of the theoretical value) MS: M/e = 641.1; Xma: 500.0 nm. Example 160 78 (8S)-5-chloro-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro [cyclopenta [g]isoquinoline-8,2'-cyclopentalb]-naphthalenel-3 carbaldehyde oxime (160) Yield: (95% of the theoretical value) MS: M/e = 551.1; ?ma: 500.0 nm. Example 161 (8S)-5-chloro-1-0-({(1E)-[(8S)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo 1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[glisoquinoline-8,2'-cyclopenta[b] naphthalene]-3-yl)methyleneamino)-p-D-glucopyranose (161) Yield: (95% of the theoretical value) MS: M/e = 713.1; Xma: 500.0 nm. Example 162 (8S)-5-chloro-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro [cyclopenta [g] isoquinoline-8,2'-cyclopenta [b] -naphthalene]-3 carbaldehyde-phenylsemicarbazone (162) Yield: (95% of the theoretical value) MS: M/e = 669.1; )m: 500.0 nm. Example 163 (8S)-5-chloro-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[glisoquinoline-8,2'-cyclopenta[b]-naphthalenel-3 carbaldehydesemicarbazone (163) Yield: (90% of the theoretical value) MS: M/e = 593.0; Xma: 500.0 nm. Example 164 (8S)-5-chloro-2-piperidino-4-yl-N'-[(1E)-[(8S)-(4',9,9'-trihydroxy-6'-methoxy 1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[giisoquinoline-8,2' cyclopenta [b]-naphthalenel-3-yl)methylene]acetohydrazide (164) Yield: (95% of the theoretical value) MS: M/e = 675.1; ?,,ma: 500.0 nm. Example 165 (8S)-5-chloro-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopenta [b]-naphthalene]-3 carbaldehyde O-(3-chlorobenzyl)oxime (165) 79 Yield: (90% of the theoretical value) MS: M/e =675.0; Xrmax: 500.0 rnm. Example 166 (8S)-5-chloro-N'-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo 1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[glisoquinoline-8,2'-cyclopenta[b] naphthalene] -3-yl)methylene] a-2-methyl-1,3-thiazole-4yl-carbohydrazide (166) Yield: (95% of the theoretical value) MS: M/e = 675.0; )ma: 500.0 nm. Example 167 (8S)-5-chloro-2-(1H-imidazole-1-yl)-N'-[(1E)-(4',9,9'-trihydroxy-6'-methoxy 1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[g]isoquinoline-8,2' cyclopenta [b] -naphthalene]-3-yi)methylene] acetohydrazide (1647) Yield: (90% of the theoretical value) MS: M/e = 658.1; kam,: 500.0 rnm. Example 168 (8S)-5-chloro-2-(acetylamino)-Nl-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8' pentaoxo-1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[glisoquinoline-8,2' cyclopenta [b]-naphthalene]-3-yl)methylene]acetohydrazide (164) Yield: (95% of the theoretical value) MS: M/e = 649.0; Xmax: 500.0 nm. Example 169 (8S)-5-chloro-2-(4-methylpiperazine-1-yl)-N-[(1E)-(4',9,9'-trihydroxy-6'-methoxy 1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[g]isoquinoline-8,2' cyclopenta[b]-naphthalene]-3-yl)methylenelacetohydrazide (169) Yield: (60% of the theoretical value) MS: M/e = 690.1; ,ma: 500.0 nim. Example 170 (8S)-5-chloro-2-morpholine-4-yl-N'-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8' pentaoxo-1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[glisoquinoline-8,2' cyclopenta[b]-naphthalene]-3-yl)methylene]acetohydrazide (170) Yield: (60% of the theoretical value) MS: M/e = 677.1; Xmax: 500.0 rnm. Example 171 80 (8S)-5-chloro-2-(methylamino)-N'-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8' pentaoxo-1,1',2,3',5',6,7,8'-octahydrospiro[cyclopentalg]isoquinoline-8,2' cyclopenta [b] -naphthalene] -3-yl)methylene acetohydrazide (171) Yield: (70% of the theoretical value) MS: M/e = 621.1; Xmax: 500.0 nm. Example 172 (8S)-5-chloro-2-[isopropyl(methyl)amino]-A-[(1E)-(4',9,9'-trihydroxy-6'-methoxy 1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[gjisoquinoline-8,2' cyclopenta [b] -naphthalene]-3-yl)methylenel acetohydrazide (172) Yield: (95% of the theoretical value) MS: M/e = 675.1; Xma: 500.0 nm. Example 173 (8S)-5-chloro-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopenta[b]-naphthalenel-3 carbaldehyde 0-12-(dimethylamino)ethyl]-oxime (173) Yield: (60% of the theoretical value) MS: M/e = 622.0; Xma: 500.0 nm. Example 174 (8S)-5-chloro-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro [cyclopenta[g]isoquinoline-8,2'-cyclopenta [b]-naphthalene]-3 carbaldehyde 0-[3-(4-(3-chlorophenyl)-piperazine-1-yl)propyll-oxime (174) Yield: (90% of the theoretical value) MS: M/e = 787.1; Xma: 500.0 nm. Example 175 (8S)-5-chloro-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopenta[b]-naphthalenel-3 carbaldehyde O-[3-(dimethylamino)propyljoxime (175) Yield: (75% of the theoretical value) MS: M/e = 636.1; Xmax: 500.0 nm. Example 176 (8S)-5-bromo-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[glisoquinoline-8,2'-cyclopenta[b]-naphthalene]-3 carbaldehydepyridine-2-yl-hydrazone (176) 81 Yield: (95% of the theoretical value) MS: M/e = 670.9; Xma: 500.0 am. Example 177 (8S)-5-bromo-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiroIcyclopenta[gisoquinoline-8,2'-cyclopenta[b]-naphthalene]-3 carbaldehyde [4-(trifluoromethyl)pyrimidine-2-ylhydrazone (177) Yield: (95% of the theoretical value) MS: M/e = 739.9; ma: 500.0 nm. Example 178 (8S)-5-bromo-V-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo 1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[gisoquinoline-8,2'-cyclopenta[bl naphthalene] -3-yl)methylenel pyridyl-3-carbohydrazide (178) Yield: (90% of the theoretical value) MS: M/e = 699.0; Xma: 500.0 nm. Example 179 (8S)-5-bromo-N-[(1E)-(4',9,9 1 -trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo 1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopenta[b] naphthalene]-3-yl)methylene] isonicotinohydrazide (179) Yield: (90% of the theoretical value) MS: M/e = 699.0; Xma: 500.0 nm. Example 180 (8S)-5-bromo-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro [cyclopenta[g]isoquinoline-8,2'-cyclopenta[b]-naphthalene]-3 carbaldehyde-1,2,4-triazole-4-ylhydrazone (180) Yield: (70% of the theoretical value) MS: M/e = 645.9; Xma: 492.0 nm. Example 181 (8S)-5-bromo-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiroicyclopenta[glisoquinoline-8,2'-cyclopenta[bl-naphthalene]-3 carbaldehyde-4,5-dihydro-1H-imidazole-2-ylhydrazone (181) Yield: (95% of the theoretical value) MS: M/e = 662.0; Xma: 492.0 nm. Example 182 82 (8S)-5-bromo-N-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo 1,1',2,3',5',6,7,8'-octahydrospiro [cyclopenta [g]isoquinoline-8,2'-cyclopenta[b] naphthalene]-3-yl)methylene]-2-furohydrazide (182) Yield: (95% of the theoretical value) MS: M/e = 688.9; Xma: 492.0 rn. Example 183 (8S)-5-bromo-4-amino-N-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo 1,1',2,3',5',6,7,8'-octahydrospirolcyclopenta[glisoquinoline-8,2'-cyclopenta[b] naphthalene]-3-yl)methylenelbenzohydrazide (183) Yield: (95% of the theoretical value) MS: M/e = 713.0; Xmax: 500.0 nm. Example 184 (8S)-5-bromo-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopenta[b]-naphthalene]-3 carbaldehydethiosemicarbazone (184) Yield: (95% of the theoretical value) MS: M/e = 653.0; Amax: 500.0 nm. Example 185 (8S)-5-bromo-N-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo 1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopenta[b] naphthalene]-3-yl)methylene]thiophene-2-carbohydrazide (185) Yield: (95% of the theoretical value) MS: M/e = 704.0; Xmax: 492.0 nm. Example 186 (8S)-5-bromo-2-(1H-indole-3-yl)-N'-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8' pentaoxo-1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[gjisoquinoline-8,2' cyclopenta[b]-naphthalene]-3-yl)methylenelacetohydrazide (186) Yield: (95% of the theoretical value) MS: M/e = 751.1; Xma,: 500.0 nm. Example 187 (8S)-5-bromo-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopenta[b]-naphthalene]-3 carbaldehyde(4-methylpiperazine-1-yl)hydrazone (187) 83 Yield: (95% of the theoretical value) MS: M/e = 677.1; Xmax: 500.0 nm. Example 188 (8S)-5-bromo-2-oxo-2-{(2E)-2-[(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo 1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[gjisoquinoline-8,2'-cyclopenta[b] naphthalene]-3-yl)methylene]hydrazino)acetamide (188) Yield: (95% of the theoretical value) MS: M/e = 665.0; Xma: 500.0 nm. Example 189 (8S)-5-bromo-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopenta[b]-naphthalene] 1,1',3',5',8'(2H)-pentone (189) Yield: (95% of the theoretical value) MS: M/e = 709.9; Xmax: 492.0 nm. Example 190 (8S)-5-bromo-{(2E)-2-[(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo 1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[gjisoquinoline-8,2'-cyclopenta[b] naphthalene]-3-yl)methylenehydrazinolacetonitrile (190) Yield: (95% of the theoretical value) MS: M/e = 661.0; Xmax: 500.0 nm. Example 191 (8S)-5-bromo-2-amino-N'-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo 1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[gjisoquinoline-8,2'-cyclopenta[b] naphthalene] -3-yl)methylenel benzohydrazide (191) Yield: (70% of the theoretical value) MS: M/e = 713.0; ?ma: 492.0 nm. Example 192 (8S)-5-bromo-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopenta[bI-naphthalene]-3 carbaldehyde 0-[2-morpholine-4-yI-ethyl)oxime (192) Yield: (95% of the theoretical value) MS: M/e = 708.0; kmax: 500.0 nm. Example 193 84 (8S)-5-bromo-(2E)-2-[(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo 1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta [g]isoquinoline-8,2'-cyclopenta [b] naphthalene]-3-yl)methylenel hydrazinecarboximidamide (193) Yield: (95% of the theoretical value) MS: M/e = 636.0; Xmax: 500.0 nm. Example 194 (8S)-5-bromo-2-(dimethylamino)-'-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8' pentaoxo-1,1',2,3',5',6,7,8'-octahydrospirolcyclopenta[gjisoquinoline-8,2' cyclopenta [b] -naphthalene] -3-yl)methylene] acetohydrazide (194) Yield: (95% of the theoretical value) MS: M/e = 679.0; ?ma: 500.0 nm. Example 195 (8S)-5-bromo-1-[2-oxo-2-((2E)-2-{[(8S)-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8' pentaoxo-1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[glisoquinoline- 8
,
2
'
cyclopenta [b]-naphthalene]-3-yl)methylene)hydrazino)ethyl pyridinium chloride (195) Yield: (95% of the theoretical value) MS: M/e = 713.0; kmax: 500.0 nm. Example 196 (8S)-5-bromo-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5', 6
,
7
,
8
'
octahydrospiro [cyclopenta [g] isoquinoline-8,2'-cyclopenta [b]-naphthalene] -3 carbaldehyde 0-methyloxime (196) Yield: (95% of the theoretical value) MS: M/e = 609.0; Xmax: 492.0 am. Example 197 (8S)-5-bromo-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopentalglisoquinoline-8,2'-cyclopentalb]-naphthalene]-3 carbaldehyde-O-benzyloxime (197) Yield: (95% of the theoretical value) MS: M/e = 685.0; max: 492.0 nm. Example 198 85 (8S)-5-bromo-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro [cyclopenta [g]isoquinoline-8,2'-cyclopenta [b]-naphthalene]-3 carbaldehyde oxime (198) Yield: (95% of the theoretical value) MS: M/e = 595.0; Xma: 492.0 nm. Example 199 (8S)-5-bromo-1-0-({(1E)-[(8S)-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo 1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[glisoquinoline-8,2'-cyclopenta[b] naphthalene]-3-yl)methylene}amino)-p-D-glucopyranose (199) Yield: (90% of the theoretical value) MS: M/e = 757.0; a.m: 500.0 nm. Example 200 (8S)-5-bromo-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5', 6
,
7
,
8
'
octahydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopenta[b]-naphthalenel-3 carbaldehyde-phenylsemicarbazone (200) Yield: (90% of the theoretical value) MS: M/e = 713.0; Xma,: 500.0 nm. Example 201 (8S)-5-bromo-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopentalg]isoquinoline-8,2'-cyclopenta[b]-naphthalenel-3 carbaldehydesemicarbazone (201) Yield: (90% of the theoretical value) MS: M/e = 637.0; X,.ma: 492.0 nm. Example 202 (8S)-5-bromo-2-piperidino-4-yl-NV-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8' pentaoxo-1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[glisoquinoline-8,2' cyclopenta[b]-naphthalene]-3-yl)methylene]acetohydrazide (201) Yield: (90% of the theoretical value) MS: M/e = 719.0; Xnax: 500.0 nm. Example 203 (8S)-5-bromo-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopentalb]-naphthalene]- 3 carbaldehyde O-(3-chlorobenzyl)oxime (203) 86 Yield: (95% of the theoretical value) MS: M/e = 718.0; Xmax: 492.0 nm. Example 204 (8S)-5-bromo-Nl-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo 1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[glisoquinoline-8,2'-cyclopenta[b] naphthalene] -3-yl)methylene]-2-methyl-1,3-thiazole-4yl-carbohydrazide (204) Yield: (95% of the theoretical value) MS: M/e = 718.9; ?ma: 492.0 nm. Example 205 (8S)-5-bromo-2-(1H-imidazole-1-yl)-N-[(1E)-(4',9,9'-trihydroxy-6'-methoxy 1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[gjisoquinoline-8,2' cyclopenta[b]-naphthalene]-3-yl)methylenel acetohydrazide (205) Yield: (95% of the theoretical value) MS: M/e = 702.0; Xmax: 500.0 nm. Example 206 (8S)-5-bromo-2-(acetylamino)-N"-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8' pentaoxo-1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[glisoquinoline- 8
,
2
'
cyclopenta [b]-naphthalene]-3-yl)methylene] acetohydrazide (206) Yield: (95% of the theoretical value) MS: M/e = 693.0; max: 492.0 nm. Example 207 (8S)-5-bromo-2-(4-methylpiperazine-1-yI)-N-[(1E)-(4',9,9'-trihydroxy-6'-methoxy 1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8'-octahydrospiro cyclopenta[glisoquinoline-8,2' cyclopenta [b] -naphthalene]-3-yl)methylene] acetohydrazide (207) Yield: (90% of the theoretical value) MS: M/e = 734.1; Xma: 500.0 nm. Example 208 (8S)-5-bromo-2-morpholine-4-yl-NY-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8' pentaoxo-1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[g]isoquinoline-8,2' cyclopenta [bj-naphthalene]-3-yl)methylene]acetohydrazide (208) Yield: (95% of the theoretical value) MS: M/e = 721.1; ,max: 500.0 nn. Example 209 87 (8S)-5-bromo-2-(methylamino)-N'-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8' pentaoxo-1,1',2,3',5',6,7,8'-octahydrospiro [cyclopenta [g]isoquinoline-8,2' cyclopenta[b]-naphthalene]-3-yl)methyleneacetohydrazide (209) Yield: (95% of the theoretical value) MS: M/e = 665.0; Xma: 500.0 rnm. Example 210 (8S)-5-bromo-2-[isopropyl(methyl)amino]-N'-[(1E)-(4',9,9'-trihydroxY-6'-methoxy 1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[giisoquinoline-8,2' cyclopenta [b] -naphthalene]-3-yl)methylene] acetohydrazide (210) Yield: (95% of the theoretical value) MS: M/e = 707.0; Xma: 500.0 nm. Example 211 (8S)-5-bromo-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro [cyclopenta [g] isoquinoline-8,2'-cyclopenta [b]-naphthalene]-3 carbaldehyde 0-[2-(dimethylamino)ethyloxime (211) Yield: (95% of the theoretical value) MS: M/e = 666.0; Ama: 500.0 nm. Example 212 (8S)-5-bromo-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro cyclopenta[g]isoquinoline-8,2'-cyclopenta[b]-naphthalene]-3 carbaldehyde 0-[3-(4-(3-chlorophenyl)-piperazine-1-yl)propylloxime (212) Yield: (95% of the theoretical value) MS: M/e = 831.0; Xmax: 500.0 nm. Example 213 (8S)-5-bromo-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopenta[b]-naphthalene]-3 carbaldehyde 0-[3-(dimethylamino)propyl]oxime (213) Yield: (95% of the theoretical value) MS: M/e = 680.0; Xma: 492.0 nm. Example 214 (8S)-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospirolcyclopenta[gisoquinoline-8,2'-cyclopenta[b]-naphthalene]-3 carbaldehyde 0-isopropyloxime (214) 88 Yield: (95% of the theoretical value) MS: M/e = 559.2; ?,a.: 500.0 nm. Example 215 (8S)-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[gJisoquinoline-8,2'-cyclopenta[b]-naphthalenel-3 carbaldehyde 0-n-hexyloxime (215) Yield: (99% of the theoretical value) MS: M/e = 601.3; Xma: 500.0 nm. Example 216 (8S)-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[glisoquinoline-8,2'-cyclopenta[b]-naphthalene]-3 carbaldehyde O-(4-fluorobenzyl)oxime (216) Yield: (99% of the theoretical value) MS: M/e = 625.2; )max: 500.0 nm. Example 217 (8S)-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopentalg]isoquinoline-8,2'-cyclopenta[b]-naphthalene]-3 carbaldehyde 0-(4-chlorobenzyl)oxime (217) Yield: (99% of the theoretical value) MS: M/e = 641.2; Xmax: 500.0 nm. Example 218 (8S)-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5', 6
,
7
,
8
'
octahydrospirolcyclopenta[g]isoquinoline-8,2'-cyclopenta[b]-naphthalene]-3 carbaldehyde O-(3-fluorobenzyl)oxime (218) Yield: (99% of the theoretical value) MS: M/e = 625.3; Xmax: 500.0 nm. Example 219 (8S)-5-chloro-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopenta[b]-naphthalenel-3 carbaldehyde 0-isopropyloxime (219) Yield: (80% of the theoretical value) MS: M/e = 593.2; Xmax: 500.0 nm. Example 220 89 (8S)-5-chloro-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta [g] isoquinoline-8,2'-cyclopenta[b]-naphthalene]-3 carbaldehyde O-n-hexyloxime (220) Yield: (90% of the theoretical value) MS: M/e = 635.3; Xmax: 500.0 nm. Example 221 (8S)-5-chloro-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta [g]isoquinoline-8,2'-cyclopenta[b]-naphthalene]-3 carbaldehyde O-(4-fluorobenzyl)oxime (221) Yield: (85% of the theoretical value) MS: M/e = 659.3; Xma: 500.0 nm. Example 222 (8S)-5-chloro-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[glisoquinoline-8,2'-cyclopenta[b]-naphthalene- 3 carbaldehyde O-(4-chlorobenzyl)oxime (222) Yield: (80% of the theoretical value) MS: M/e = 675.3; kma: 500.0 nm. Example 223 (8S)-5-chloro-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[glisoquinoline-8,2'-cyclopenta[b] -naphthalene]- 3 carbaldehyde O-(3-fluorobenzyl)oxime (223) Yield: (80% of the theoretical value) MS: M/e = 659.3; kma: 500.0 rim. Example 224 (8S)-5-bromo-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[glisoquinoline-8,2'-cyclopenta[b]-naphthalene]-3 carbaldehyde 0-isopropyloxime (224) Yield: (90% of the theoretical value) MS: M/e = 639.3; )ma,: 492.0 nm. Example 225 (8S)-5-bromo-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[glisoquinoline-8,2'-cyclopenta[b]-naphthalenel-3 carbaldehyde 0-n-hexyloxime (225) 90 Yield: (95% of the theoretical value) MS: M/e = 679.3; Xmax: 492.0 nm. Example 226 (8S)-5-bromo-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro [cyclopenta [g]isoquinoline-8,2'-cyclopenta [b]-naphthalene]-3 carbaldehyde O-(4-fluorobenzyl)oxime (226) Yield: (95% of the theoretical value) MS: M/e = 703.3; kma,: 492.0 nm. Example 227 (8S)-5-bromo-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[g] isoquinoline-8,2'-cyclopenta[b]-naphthalene]-3 carbaldehyde 0-(4-chlorobenzyl)oxime (227) Yield: (95% of the theoretical value) MS: M/e = 719.3; Xma. 492.0 nm. Example 228 (8S)-5-bromo-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[gJisoquinoline-8,2'-cyclopenta[bI-naphthalenel-3 carbaldehyde O-(3-fluorobenzyl)oxime (228) Yield: (95% of the theoretical value) MS: M/e = 705.3; ?ma: 492.0 nm. Example 229 (8S)-5-iodo-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[g]isoquinoline- 8
,
2 '-cyclopenta [b]-naphthalene]-3 carbaldehyde O-isopropyloxime (229) Yield: (99% of the theoretical value) MS: M/e = 685.3; Xmax: 500.0 nm. Example 230 (8S)-5-iodo-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro [cyclopenta[g] isoquinoline-8,2'-cyclopenta[b]-naphthalene]-3 carbaldehyde O-n-hexyloxime (230) Yield: (99% of the theoretical value) MS: M/e = 727.4; Xma.: 500.0 nm. Example 231 91 (8S)-5-iodo-4',9,9'-tribydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro cyclopenta[glisoquinoline-8,2'-cyclopenta[b]-naphthalene]
-
3 carbaldehyde 0-(4-fluorobenzyl)oxime (231) Yield: (99% of the theoretical value) MS: M/e = 751.3; Ximax: 500.0 rnm. Example 232 (8S)-5-iodo-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro Icyclopenta [g] isoquinoline-8,2'-cyclopenta [b]-naphthalene]-3 carbaldehyde 0-(4-chlorobenzyl)oxime (232) Yield: (99% of the theoretical value) MS: M/e = 767.3; Xma: 500.0 nm. Example 233 (8S)-5-iodo-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[gJisoquinoline-8,2'-cyclopenta[bl-naphthalenel-3 carbaldehyde 0-(3-fluorobenzyl)oxime (233) Yield: (99% of the theoretical value) MS: M/e = 751.3; Ama: 500.0 nm. Example 234 (8S)-5-iodo-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[glisoquinoline-8,2'-cyclopenta[bl-naphthalene]-3 carbaldehyde O-benzyloxime (234) Yield: (99% of the theoretical value) MS: M/e = 733.3; ?ma,: 500.0 nm. Example 235 (8S)-5-iodo-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta [g]isoquinoline-8,2'-cyclopenta[b]-naphthalene]-3 carbaldehyde 0-12-morpholine-4-yI-ethyl)oxime (235) Yield: (99% of the theoretical value) MS: M/e = 756.3; Xma: 500.0 nm. Example 236 (8S)-5-iodo-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopenta[b]-naphthalenel-3 carbaldehyde 0-methyloxime (236) 92 Yield: (95% of the theoretical value) MS: M/e = 657.3; X.ma.: 492.0 nm. Example 237 (8S)-5-iodo-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro [cyclopenta[g]isoquinoline-8,2'-cyclopenta[b]-naphthalene]- 3 carbaldehyde O-(3-chlorobenzyl)oxime (237) Yield: (99% of the theoretical value) MS: M/e = 767.3; Xm.: 492.0 rnm. Example 238 (8S)-5-iodo-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro[cyclopenta[glisoquinoline-8, 2 '-cyclopenta[b]-naphthalenel-3 carbaldehyde 0-[3-(4-(3-chlorophenyl)-piperazine-1-yl)propylloxime (238) Yield: (99% of the theoretical value) MS: M/e = 879.4; Xma: 500.0 nm. Example 239 (8S)-5-iodo-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8' octahydrospiro Icyclopenta [g] isoquinoline-8,2'-cyclopenta [b] -naphthalene] -3 carbaldehyde oxime (239) Yield: (99% of the theoretical value) MS: M/e = 643.3; Xma: 492.0 rim. Example 240 (8S)-5-iodo-2-(4-methylpiperazine-1-yl)-N'-[(1E)-(4',9,9'-trihydroxy-6'-methoxy 1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[glisoquinoline-8,2' cyclopenta [b] -naphthalene]-3-yl)methylene] acetohydrazide (240) Yield: (99% of the theoretical value) MS: M/e = 782.3; Xma: 500.0 nm. Example 241 (8S)-5-iodo-2-morpholine-4-yl-N'-[(1E)-(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8' pentaoxo-1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[glisoquinoline-8,2' cyclopenta[b]-naphthalenel-3-yl)methylenelacetohydrazide (241) Yield: (99% of the theoretical value) MS: M/e = 782.3; Xmax: 500.0 rnm. Example 242 93 (8S)-5-iodo-2-oxo-2- {(2E)-2-[(4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo 1,1',2,3',5',6,7,8'-octahydrospiro [cyclopenta[g]isoquinoline-8,2'-cyclopenta [b] naphthalene]-3-yl)methylene] hyd razino) acetamide (242) Yield: (99% of the theoretical value) MS: M/e = 713.3; Xma: 500.0 rim. Example 243 (8S)-4',9,9'-trihydroxy-6'-ethoxy-3-[(1E,3E)-penta-1,3-dienyl]-6,7 dihydrospiro'cyclopenta[g-isoquinoline-8,2'-cyclopenta[b]-naphthalene]-1,1' 3',5',8'(2H)-pentone (243) Five (5) mg (0.0095 mmol) fredericamycin (1) are suspended in 2.0 ml ethanol. Under N 2 atmosphere, 90 mg sodium acetate are added and boiled under reflux. After a few minutes, the suspension turns into a deep blue solution. After 24 h it is cooled, transferred onto water and shaken out with ethyl acetate (0.1% CF 3 COOH). After drying and concentration, a chromatographically homogenous, red powder is left. Yield: 5.0 mg (97% of the theoretical value) MS = 554 (M+H)+; Xma: 504.0 nm. Example 244 (8S)-4',9,9'-trihydroxy-6'-n-butoxy-3-[(1E,3E)-penta-1,3-dienyl]-6,7 dihydrospirocyclopenta[g]isoquinoline-8,2'-cyclopenta [b]-naphthalene]-1,1 ' 3',5',8'(2H)-pentone (244) Six (6) mg (0.0114 mmol) fredericamycin (1) are suspended in 3.0 ml n-butanol. Under N 2 atmosphere, 50 mg potassium acetate are added and heated to 1000 C. After a few minutes, the suspension turns into a deep blue solution. The solution is left for 1 h at this temperature, and is then cooled. It is transferred onto water and shaken out with ethyl acetate (0.1% CF 3 COOH). After drying and concentration, a chromatographically homogenous red powder is left. Yield: 6.2 mg (96% of the theoretical value) MS = 582 (M)+; ?ma): 500.0 nm. Example 245 (8S)-4',9,9'-trihydroxy-6'-n-isopropyloxy-3-[(1E,3E)-penta-1,3-dienyll-6,7 dihydrospirocyclopentalg]isoquinoline-8,2'-cyclopenta[b]-naphthalene-1,1' 3',5',8'(2H)-pentone (245) 94 Five (5) mg (0.0095 mmol) fredericamycin (1) are suspended in 3.0 ml n-propanol. Under
N
2 atmosphere, 50 mg potassium acetate (anhydrous) are added and heated to 800 C. After a few minutes, the suspension turns into a deep blue solution. The solution is left for 48 h at this temperature, and is then cooled. It is transferred onto water and shaken out with ethyl acetate (0.1% CF 3 COOH). After drying and concentration, a chromatographically homogenous red powder is left. Yield: 3.7 mg (70% of the theoretical value) MS = 568 (M+H)+; X ma: 500.0 nm. Example 246 (8S)-4',9,9'-trihydroxy-6'-(2-dimethylaminoethoxy)-3-[(1E,3E)-penta-1,3-dienyl]-6,7 dihydrospiro[cyclopenta[gisoquinoline-8,2'-cyclopenta[b]-naphthalene]-1,1' 3',5',8'(2H)-pentone (246) 6.1 mg (0.01159 mmol) fredericamycin (1) are suspended in 3.5 ml N,N Dimethylaminoethanol. Under N 2 atmosphere, 52 mg anhydrous potassium acetate are added and heated to 800 C. After a few minutes, the suspension turns into a deep blue solution. The solution is left for 1.5 h at this temperature, and is then cooled. It is transferred onto water and shaken out with ethyl acetate (0.1% CF 3 COOH). After drying and concentration, a chromatographically homogenous red powder is left. Yield: 2.4 mg (36% of the theoretical value); MS = 597 (M+H)+; Xm: 504.0 nm. Example 247 (8S)-5-bromo-4',9,9'-trihydroxy-6'-(2-dimethylaminoethoxy)-3-[(1E,3E)-penta-1,3 dienyl]-6,7-dihydrospiro[cyclopenta [g]isoquinoline-8,2'-cyclopenta [b]-naphthalene] 1,1'-3',5',8'(2H)-pentone (247) Ten (10.0) mg (0.019 mmol) bromofredericamycin (14) are suspended in 3.0 ml ethanol. Under N 2 atmosphere, 50 mg anhydrous potassium acetate are added and heated to 800 C. After a few minutes, the suspension turns into a deep blue solution. The solution is left for 48 h at this temperature, and is then cooled. It is transferred onto water and shaken out with ethyl acetate (0.1% CF 3 COOH). After drying and concentration, a chromatographically homogenous red powder is left. Yield: 7.2 mg (71 % of the theoretical value); MS = 632/634 (M+H)+; XAma: 504.0 rim. Example 248 95 (8S)-4',9,9'-trihydroxy-6'-allyloxy-3-[(1E,3E)-penta-1,3-dienyl]-6,7 dihydrospiro [cyclopenta [g]isoquinoline-8,2'-cyclopenta [b]-naphthalene]-1,1' 3',5',8'(2H)-pentone (248) 9.6 mg (0.01824 mmol) fredericamycin (1) are suspended in 3.0 ml allyl alcohol. Under N 2 atmosphere, 58 mg anhydrous potassium acetate are added and heated to 700 C. After a few minutes, the suspension turns into a deep blue solution. The solution is left for 2.5 h at this temperature, and is then cooled. It is transferred onto water and shaken out with ethyl acetate (0.1% CF 3 COOH). After drying and concentration, a chromatographically homogenous red powder is left. Yield: 9.2 mg (91 % of the theoretical value); MS = 566 (M+H)+; Xma: 500.0 nm. The compounds 249, 250, 251, 252, 253, 254, 255 were generated analogously to the instructions 244-248: Example 249 (8S)-4',9,9'-trihydroxy-6'-(2-hydroxyethoxy)-3-[(1E,3E)-penta-1,3-dienyl]-6,7 dihydrospiro[cyclopenta[gJisoquinoline-8,2'-cyclopenta[b]-naphthalenel-1,1' 3',5',8'(2H)-pentone (249) Yield: 5.2 mg (52 % of the theoretical value); MS = 569 (M)+; Ama: 499.0 nm. Example 250 (8S)-4',9,9'-trihydroxy-6'-benzyloxy-3-[(1E,3E)-penta-1,3-dienyl]-6,7 dihydrospiro[cyclopenta[gjisoquinoline-8,2'-cyclopenta[b]-naphthalene]-1,1' 3',5',8'(2H)-pentone (250) Yield:10.2 mg (99 % of the theoretical value); MS = 616 (M+H)+; Xma: 504.0 nm. Example 251 (8S)-4',9,9'-trihydroxy-6'-cyclopropylmethoxy-3-[(1E,3E)-penta-1,3-dienyl]-6,7 dihydrospiro[cyclopenta[gjisoquinoline-8,2'-cyclopenta[b]-naphthalene]-1,1' 3',5',8'(2H)-pentone (251) Yield: 12.9 mg (99 % of the theoretical value); MS = 580 (M)+; ma: 500.0 nm. Example 252 96 1-Desoxy-5-C-[(8R)-4',9,9'-trihydroxy-6'-ethoxy-1,1',3',5',8'-pentaoxo 1,1 ',2,3',5',6',7',8'-octahydrospiro [cyclopenta [g] isoquinoline-8,2'-cyclopenta [b] naphthalene]-3-yl pentitol (252) Yield: 2.0 mg (20 % of the theoretical value); MS = 622 (M+H)+; Xma: 499.0 nm. Example 253 (8S)-4',9,9'-trihydroxy-6'-(2-t-butoxycarbonylaminoethoxy)-3-[(1E,3E)-penta-1,3 dienyl]-6,7-dihydrospiro[cyclopenta[gJisoquinoline-8,2'-cyclopenta[b]-naphthalene] 1,1'-3',5',8'(2H)-pentone (253) Yield: 12.9 mg (99 % of the theoretical value); MS = 669 (M)+; Xma: 500.0 nm. Example 254 (8S)-4',9,9'-trihydroxy-6'-(2-N,N-diisopropylaminoethoxy)-3-[(1E,3E)-penta-1,3 dienyl]-6,7-dihydrospiro [cyclopenta [g]isoquinoline-8,2'-cyclopenta [b]-naphthalene] 1,1'-3',5',8'(2H)-pentone (249) Yield: 5.8 mg (48 % of the theoretical value); MS = 653 (M+H)+; ma: 500.0 nm. Example 255 1-Desoxy-5-C-[(8R)-4',9,9'-trihydroxy-6'-ethoxy-1,1',3',5',8'-pentaoxo 1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopentab] naphthalene]-3-yl]pentitol (255) Yield: 5.5 mg (50 % of the theoretical value); MS = 594 (M+H)+; ?ma,: 500.0 nm. Example 256 (8S)-4',9,9'-trihydroxy-6'-(2-bromoethoxy)-3-[(1E,3E)-penta-1,3-dienyl]-6,7 dihydrospiro [cyclopenta[g]isoquinoline-8,2'-cyclopenta[b]-naphthalene] -1,1' 3',5',8'(2H)-pentone (256) 10.6 mg (0.02014 mmol) fredericamycin (1) are suspended in 2.0 ml bromoethanol. Under
N
2 atmosphere, 150 mg anhydrous potassium acetate are added and heated to 1200 C. After a few minutes, the suspension turns into a deep blue solution. After 12 hours, addition of another 150 mg potassium acetate. The solution is left for another 12 h at this temperature, and is then cooled. It is transferred onto water and shaken out with ethyl acetate (0.1% 97
CF
3 COOH). After drying and concentration, a chromatographically homogenous red powder is left. Yield: 11.5 mg (99 % of the theoretical value); MS = 632/634 (M+H)+; Xma: 499.0 im. Example 257 (8S)-5-iodo-4',9,9'-trihydroxy-6'-cyclopropylamino-3-[(1E,3E)-penta-1,3-dienyl]-6,7 dihydrospiro[cyclopenta[glisoquinoline-8,2'-cyclopenta[b]-naphthalene]-1,1' 3',5',8'(2H)-pentone (257) Five (5.0) mg (7.5 pimol) 5-iodofredericamycin (15) are dissolved under argon in 1.0 ml anhydrous DMF. After addition of 0.64 mg (11.2 ptmmol) cyclopropylamine, it is stirred at room temperature for 3 h. Excess cycloprolylamine and DMF are removed at high vacuum. After drying and concentration, a chromatographically homogenous red powder is left. Yield: 5.1 mg (99 %); MS = 691.3 (M+H)+; 2ama: 504.0 nn. Example 258 (8S)-5-iodo-4',9,9'-trihydroxy-6'-n-butylamino-3-[(1E,3E)-penta-1,3-dienyil-6,7 dihydrospiro[cyclopenta[glisoquinoline-8,2'-cyclopenta[b]-naphthalene]-1,1' 3',5',8'(2H)-pentone (258) Five (5.0) mg (7.5 pmol) 5-iodofredericamycin (15) are dissolved under argon in 1.0 ml anhydrous DMF. After addition of 0.82 mg (11.2 pimol) n-butylamine, it is stirred at room temperature for 20 h. Excess n-butylamine and DMF are removed at high vacuum. After drying and concentration, a chromatographically homogenous red powder is left. Yield: 5.3 mg (99 %); MS = 707.3 (M+H)+; ?ma: 504.0 nm. Example 259 (8S)-5-bromo-4',9,9'-trihydroxy-6'-n-butylamino-3-[(1E,3E)-penta-1,3-dienyl]-6,7 dihydrospiro[cyclopentaglisoquinoline-8,2'-cyclopenta b]-naphthalenel-1,1' 3',5',8'(2H)-pentone (259) Five (5.0) mg (8.1 pmol) 5-bromofredericamycin (15) are dissolved under argon in 1.0 ml anhydrous DMF. After addition of 0.89 mg (12.2 pmmol) n-butylamine, it is stirred at room temperature for 20 h. Excess n-butylamine and DMF are removed at high vacuum. After drying and concentration, a chromatographically homogenous red powder is left. Yield: 5.3 mg (99 %); MS = 659.4/661.4 (M+H)+; ma.: 504.0 nrm.
98 Example 260 (8S)-4',9,9'-trihydroxy-6'-cyclopropylamino-3-[(1E,3E)-penta-1,3-dienyl]-6,7 dihydrospiro cyclopenta[g]isoquinoline-8,2'-cyclopenta[b]-naphthalene]-1,1' 3',5',8'(2H)-pentone (260) Five (5.0) mg (9.3 pmol) fredericamycin (1) are dissolved under argon in 1.0 ml anhydrous DMF. After addition of 2.12 mg (37.2 pmmol) cyclopropylamine, it is stirred at room temperature for 2 h. Excess cyclopropylamine and DMF are removed at high vacuum. After drying and concentration, a chromatographically homogenous red powder is left. Yield: 5.1 mg (99 %); MS = 565.4 (M+H)+; Xmax: 510.0 nm. Example 261 (8S)-4',9,9'-trihydroxy-6'-anilino-3-[(1E,3E)-penta-1,3-dienyl]-6,7 dihydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopenta[b]-naphthalene]-1,1' 3',5',8'(2H)-pentone (261) Five (5.0) mg (9.3 pmol) fredericamycin (1) are dissolved under argon in 1.0 ml anhydrous DMF. After addition of 3.46 mg (37.2 immol) aniline and 37.2 pLg stannous(IV)chloride (1.0 M in CH 2 C1 2 ), it is heated to 600 C. The reaction mixture is stirred for 24 h, and then excess diethanolaminomethyl polystyrene resin is added. Stir for 1 h. Exhaust off the resin and wash with DMF. The organic phase is concentrated at high vacuum. A chromatographically homogenous red powder is left. Yield: 5.5 mg (99 %); MS = 601.1 (M+H)+; max: 504.0 nm. Example 262 (8S)-4',9,9'-trihydroxy-6'-piperidino-3-[(1E,3E)-penta-1,3-dienyl]-6,7 dihydrospirolcyclopentalglisoquinoline-8,2'-cyclopenta[b]-naphthalenel-1,1' 3',5',8'(2H)-pentone (262) Five (5.0) mg (9.3 pmol) fredericamycin (1) are dissolved under argon in 1.0 ml anhydrous DMF. After addition of 3.16 mg (37.2 pmmol) piperidine, it is stirred for 22 h at room temperature. Excess amine and DMF are removed in high vacuum. A chromatographically homogenous red powder is left. Yield: 5.5 mg (99 %); MS = 593.4 (M+H)+; Xmax: 504.0 nm.
99 Example 263 (8S)-4',9,9'-trihydroxy-6'-dimethylamino-3-[(1E,3E)-penta-1,3-dienyl]-6,7 dihydrospiro[cyclopenta[gisoquinoline-8,2'-cyclopentalb]-naphthalene]-1,1' 3',5',8'(2H)-pentone (263) Five (5.0) mg (9.3 pimol) fredericamycin (1) are dissolved under argon in 1.0 ml anhydrous DMF. After addition of 1.67 mg (37.2 pmmol) dimethylamine (2M in MeOH), it is stirred for 4 h at room temperature. Excess amine and DMF are removed in high vacuum. A chromatographically homogenous red powder is left. Yield: 5.5 mg (99 %); MS = 553.6 (M+H)+; Xma: 526.0 nm. Example 264 (8S)-4',9,9'-trihydroxy-6'-isopropylamino-3-[(1E,3E)-penta-1,3-dienyll-6,7 dihydrospiro[cyclopentalg]isoquinoline-8,2'-cyclopenta[b]-naphthalene]-1,1' 3',5',8'(2H)-pentone (264) Five (5.0) mg (9.3 pmol) fredericamycin (1) are dissolved under argon in 1.0 ml anhydrous DMF. After addition of 2.19 mg (37.2 pmmol) isopropylamine, it is stirred for 4 h at room temperature. Excess amine and DMF are removed in high vacuum. A chromatographically homogenous red powder is left. Yield: 5.2 mg (99 %); MS = 567.3 (M+H)+; Xmax: 504.0 nm. Example 265 (8S)-4',9,9'-trihydroxy-6'-methylamino-3-[(1E,3E)-penta-1,3-dienyl]-6,7 dihydrospiro[cyclopenta[glisoquinoline-8,2'-cyclopenta[b]-naphthalene]-1,1' 3',5',8'(2H)-pentone (265) Five (5.0) mg (9.3 pimol) fredericamycin (1) are dissolved under argon in 1.0 ml anhydrous DMF. After addition of 0.34 mg (11.1 pmmol) methylamine (2M in CH 3 0H), it is stirred for 19 h at room temperature. Excess amine and DMF are removed in high vacuum. A chromatographically homogenous red powder is left. Yield: 5.0 mg (99 %); MS = 539.2 (M+H)+; kma: 504.0 nm. Example 266 100 (8S)-5-iodo-4',9,9'-trihydroxy-6'-methylamino-3-[(1E,3E)-penta-1,3-dienyl]-6,7 dihydrospiro [cyclopenta [g]isoquinoline-8,2'-cyclopenta [b]-naphthalene]-1,1' 3',5',8'(2H)-pentone (266) Five (5.0) mg (7.5 pmol) 5-iodofredericamycin (1) are dissolved under argon in 1.0 ml anhydrous DMF. After addition of 0.28 mg (9.0 pmmol) methylamine (2M in CH 3 0H), it is stirred for 2 h at room temperature. Excess amine and DMF are removed in high vacuum. A chromatographically homogenous red powder is left. Yield: 5.0 mg (99 %); MS = 665.2 (M+H)+; Amax: 492.0 nm. Example 267 (8S)-4',9,9'-trihydroxy-6'-morpholino-3-[(1E,3E)-penta-1,3-dienyl]-6,7 dihydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopenta[b]-naphthalenel-1,1' 3',5',8'(2H)-pentone (267) Five (5.0) mg (9.3 pmol) fredericamycin (1) are dissolved under argon in 1.0 ml anhydrous DMF. After addition of 3.24 mg (37.2 ptmmol) morpholine, it is stirred for 18 h at room temperature. Excess amine and DMF are removed in high vacuum. A chromatographically homogenous red powder is left. Yield: 5.5 mg (99 %); MS = 595.5 (M+H)+; Amax: 518.0 nm. Example 268 (8S)-4',9,9'-trihydroxy-6'-amino-3-[(1E,3E)-penta-1,3-dienyl]-6,7 dihydrospiro [cyclopenta[g]isoquinoline-8,2'-cyclopenta[b]-naphthalene] -1,1 ' 3',5',8'(2H)-pentone (268) Five (5.0) mg (9.3 pmol) fredericamycin (1) are dissolved under argon in 1.0 ml anhydrous DMF. After addition of 0.67 mg (37.2 Vmmol) ammonia (2M in EtOH), it is stirred for 24 h at room temperature. Excess ammonia and DMF are removed in high vacuum. A chromatographically homogenous red powder is left. Yield: 4.8 mg (99 %); MS = 525.4 (M+H)+; Xmax: 504.0 nim. Example 269 (8S)-4',9,9'-trihydroxy-6'-pyrrolidino-3-[(1E,3E)-penta-1,3-dienyl]-6,7 dihydrospiro[cyclopenta[glisoquinoline-8,2'-cyclopenta[b]-naphthalene]-1,1' 3',5',8'(2H)-pentone (269) 101 Five (5.0) mg (9.3 pmol) fredericamycin (1) are dissolved under argon in 1.0 ml anhydrous DMF. After addition of 0.99 mg (13.9 pmmol) pyrrolidine, it is stirred for 19 h at room temperature. Excess amine and DMF are removed in high vacuum. A chromatographically homogenous red powder is left. Yield: 5.3 mg (99 %); MS = 579.2 (M+H)+; Xmax: 554.0 nm. Example 270 (8S)-5-bromo-4',9,9'-trihydroxy-6'-methylamino-3-[(1E,3E)-penta-1,3-dienyl]-6,7 dihydrospiro[cyclopenta[glisoquinoline-8,2'-cyclopenta[b]-naphthalene1--1,1' 3',5',8'(2H)-pentone (270) Five (5.0) mg (8.1 ptmol) 5-bromofredericamycin (1) are dissolved under argon in 1.0 ml anhydrous DMF. After addition of 0.70 mg (12.2 pimmol) cyclopropylamine, it is stirred for 5 h at room temperature. Excess cyclopropylamine and DMF are removed in high vacuum. A chromatographically homogenous red powder is left. Yield: 5.0 mg (99 %); MS = 643.4/645.4 (M+H)+; Xmax: 492.0 nm. Example 271 2-[Acetyl]-3-[(8S)-4',9,9'-trihydroxy-6'-methylamino-3-[(1E,3E)-penta-1,3-dienyl]-6,7 dihydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopenta[b]-naphthalene]-3-ylethene (271) 79.5 mg (479 pmol) (2-oxo-propyl)-phosphonic acid dimethylester are dissolved under argon in 8 ml absolute pyridine, and 60.2 pl (479 pmol) 1,1,3,3-tetramethylguanidine are added at 0* C. After 5 minutes, 80.0 mg (159.7 pimol) fredericamycin aldehyde (4) is added at 00 C. After 2 hours, 100 ml 1 M hydrochloric acid are added, and the supernatant is sucked off from the precipitate. Dry under high vacuum. Yield: 60.0 mg (69 % of the theoretical value); M/e = 542.2; Xmax: 492.0 nm. Example 272 2-[Bromoacetyl]-3-[(8S)-4',9,9'-trihydroxy-6'-methylamino-3-[(1E,3E)-penta-1,3 dienyl]-6,7-dihydrospiro [cyclopenta [gjisoquinoline-8,2'-cyclopenta [b]-naphthalene] 3-yljethene (272) Fifty (50.0) mg (92.4 pimol) acetyl fredericamycin are dissolved under argon in 5 ml absolute DMF, and then 36.9 mg (231.1 ptmol) bromine as a 1 M bromine solution in DMF 102 are added under exclusion of light. It is stirred for 23 h under exclusion of light, and then 100 ml water are added. The precipitate is sucked off and dried under high vacuum. Yield: 57.0 mg (87 % of the theoretical value) red powder; M/e = 697.9/699.9/701.9; M+; ma,: 504.0 nm. Example 273 2-[2-Amino-thiazole-4-yl]-3-[(8S)-4',9,9'-trihydroxy-6'-methylamino-3-[(1E,3E) penta-1,3-dienyl]-6,7-dihydrospiro[cyclopenta[glisoquinoline-8,2'-cyclopentalb] naphthalene]-3-yl ethene (273) Twenty (20.0) mg (28.7 mol) bromoacetyl fredericamycin (273) are dissolved under argon in 4ml absolute DMF. At room temperature, first 3.3 mg (43.0 imol) thiourea, and then 20 mg IR120 H+ are added. After 2 hours, it is filtered off the resin, and added to 50 ml water. The precipitate is dried under high vacuum. Red powder. Yield: 18.0 mg (93 % of the theoretical value); M/e = 676.1/678.1; (M+H); Xmax: 492.0 nm. Example 274 2-[2-Phenyl-thiazole-4-yl]-3-[(8S)-4',9,9'-trihydroxy-6'-methylamino-3-[(1E,3E) penta-1,3-dienyl]-6,7-dihydrospiro[cyclopenta[gisoquinoline-8,2'-cyclopentalbl naphthalene]-3-yljethene (274) Five (5.0) mg (7.2 pmol) bromoacetyl fredericamycin (273) are dissolved under argon in 1 ml absolute DMF. At room temperature, first 1.5 mg (10.8 pimol) thiobenzamide, and then 5 mg IR120 H+ are added. After 3.5 h, addition of hydrazinosulfonyl resin, and stirring for 2 h. It is filtered off the resin, and added to 10 ml water. The precipitate is dried under high vacuum. Red powder. Yield: 3.0 mg (57 % of the theoretical value); M/e = 737.2/739.2; (M+H); Xma: 492.0 nm. Example 275 2-[2-Acetylamino-thiazole-4-yl]-3-[(8S)-4',9,9'-trihydroxy-6'-methylamino-3-[(1E,3E) penta-1,3-dienyll-6,7-dihydrospiro[cyclopentalglisoquinoline-8,2'-cyclopenta[b] naphthalene]-3-yljethene (275) Five (5.0) mg (7.2 pmol) bromoacetyl fredericamycin (273) are dissolved under argon in 1 ml absolute DMF. At room temperature, first 1.3 mg (10.8 pimol) acetylthiourea, and then 5 mg IR120 H+ are added. After 22 h, addition of hydrazinosulfonyl resin, and stirring for 103 2 h. It is filtered off the resin, and added to 10 ml water. The precipitate is dried under high vacuum. Red powder. Yield: 2.0 mg (39 % of the theoretical value); M/e = 718.3/720.4; (M+H); Xma: 492.0 nm. Example 276 2-[2-Methyl-thiazole-4-yl]-3-[(8S)-4',9,9'-trihydroxy-6'-methylamino-3-[(1E,3E) penta-1,3-dienyll-6,7-dihydrospirolcyclopenta[g]isoquinoline-8,2'-cyclopenta[b] naphthalene]-3-yl] ethene (276) Five (5.0) mg (7.2 pmol) bromoacetyl fredericamycin (273) are dissolved under argon in I ml absolute DMF. At room temperature, first 0.81 mg (10.8 pmol) thioacetamide, and then 5 mg IR120 H+ are added. After 2 h, addition of hydrazinosulfonyl resin, and stirring for 2 h. It is filtered off the resin, and added to 10 ml water. The precipitate is dried at high vacuum. Red powder. Yield: 3.0 mg (62 % of the theoretical value); M/e = 675.2/677.2; (M+H); Xmax: 492.0 nm. Example 277 (8S)-4',9,9'-trihydroxy-6'-methylamino-3-[(1E,3E)-penta-1,3-dienyl]-6,7 dihydrospiro[cyclopenta[glisoquinoline-8,2'-cyclopenta[b]-naphthalene]-1-thio-,1' 3',5',8'(2H)-tetrone-thiofredericamycin (277) Ten (10.0) mg (18.5 pmol) fredericamycin (1) are dissolved under argon in 2 ml absolute pyridine. After addition of 20.5 mg (92.5 mmol) phosphorous-V-sulfide, it is heated for 12 h to 600 C. Addition of another 20.5 mg (92.5 mmol) phosphorous-V-sulfide. According to HPLC (acetonitrile/water CF 3 COOH), the reaction was complete after 1 h. It is transferred onto water and shaken out with ethyl acetate. Dry and concentrate. Purple-red powder. Yield: 5.0 mg (49 % of the theoretical value); M/e = 55.7; (M+H); Xma: 504.0 nm. Example A Water solubility of the fredericamycin derivatives The water solubility of the various fredericamycin derivatives can be determined in a 0.9% NaCl solution with a pH of 7.
104 The compounds (22) and (3) dissolve very well. Compound (6) dissolves well, and compounds (2), (10), and (13) are soluble. Compounds (5), (7), (11) and (12) are sufficiently and markedly better soluble than fredericamycin (compound (1)).

Claims (20)

1. The compounds according to the general formula Ia or Ib: O R R1~R7 Y O. 0 R1 N la HO R6"OR OH 0 07R4 0 R2 lb R3 wherein in each RI means H, CI-C 6 alkyl, cycloalkyl, Ci-C 4 alkylcycloalkyl, R2 means H, Ci-C 1 4 alkyl, C 2 -C 14 alkenyl, aryl, CI-C 4 alkylaryl, heteroaryl, Ci-C 4 alkylheteroaryl, C 2 -C 4 alkenylheteroaryl, cycloalkyl, Ci-C 4 alkylcycloalkyl, heterocycloalkyl, CI-C 4 alkylheterocycloalkyl, CmH 2 mn+o-pYp (with m = I to 6, for o = 1, p = I to 2m+o; for m = 2 to 6, o = -1, p = I to 2m+o; for m = 4 to 6, o = -2, p = I to 2m+o; Y = independently selected from the group consisting of halogen, OH, OR2 1, NH 2 , NHR2 1, NR21R22, SH, SR21), (CH 2 ),CH 2 NHCOR21, (CH 2 )rCH 2 0COR21, (CH 2 )rCH 2 NHCSR21, (CH 2 )rCH 2 S(O)nR21, with n = 0, 1, 2, (CH 2 )rCH 2 SCOR21, (CH 2 )rCH 2 0SO 2 -R21, (CH 2 )rCHO, (CH 2 )rCH=NOH, (CH 2 )rCH(OH)R2 1, -(CH 2 )rCH=NOR2 1, (CH 2 )rCH=NOCOR21, (CH 2 )rCH=NOCH 2 CONR21R22, (CH 2 )rCH=NOCH(CH 3 )CONR21R22, -(CH 2 )rCH=NOC(CH 3 ) 2 CONR2 1 R22, 106 (CH 2 )rCH=N-NHCO-R23, (CH 2 )rCH=N-NHC(O)NH-R23, (CH 2 )rCH=N-NHC(S)NH R23, (CH 2 )rCH=N-NHC(NH)NH-R23, (CH 2 )rCH=N-NHC(NH)-R23, (CH 2 )rCH=N NHCO-CH 2 NHCOR21, (CH 2 )rCH=N-0-CH 2 NHCOR21, (CH 2 )rCH=N-NHCS-R23, (CH 2 ),CH=CR24R25 (trans or cis), (CH 2 )rCOOH, (CH 2 )rCOOR21, (CH 2 )rCONR21R22, R , H R.1 RfN (CH 2 )rCH=NR2 1, (CH 2 ),CH=N-NR21 R22, RP and the (CH 2 )r chain elongated residue (CH 2 ),CH=N-N-(C 3 NX'R21 1R212R213R214) (with X' = NR215, 0, S, and R211, R212, R213, R214, R215 being independently H or CI-C 6 alkyl), (CH 2 )rCH=N-NHSO 2 aryl, -(CH 2 )rCH=N-NHSO 2 heteroaryl, with r = 0, 1, 2, 3, 4, 5, preferably 0, R21, R22 are independently H, C 1 -C 1 4 alkyl, Ci-C 1 4 alkanoyl, CI-C 6 alkylhydroxy, Ci C 6 alkoxy, CI-C 6 alkylamino, CI-C 6 alkylamino-Ci-C 6 alkyl, Ci-C 6 alkylamino-di-Ci-C 6 alkyl, cycloalkyl, CI-C 4 alkylcycloalkyl, heterocycloalkyl, Ci-C 4 alkylheterocycloalkyl, aryl, aryloyl, Ci-C 4 alkylaryl, heteroaryl, heteroaryloyl, CI-C 4 alkylheteroaryl, cycloalkanoyl, Ci-C 4 alkanoylcycloalkyl, heterocycloalkanoyl, Ci-C 4 alkanoylheterocycloalkyl, CI-C 4 alkanoylaryl, Ci-C 4 alkanoylheteroaryl, mono- and di sugar residues linked through a C atom which would carry an OH residue in the sugar, wherein the sugars are independently selected from the group consisting of glucuronic acid and its stereoisomers at all optical atoms, aldopentoses, aldohexoses, including their desoxy compounds (as e.g. glucose, desoxyglucose, ribose, desoxyribose), or R21 and R22, together with the N, form a ring with 4, 5, 6, 7, or 8 members, which may optionally contain still another heteroatom selected from the group N, 0, S, R23 independently of R2 1, has the same meanings as R21, or CH 2 -pyridinium salts, CH 2 -tri-Ci-C 6 alkylammonium salts, CONH 2 , CSNH 2 , CN, CH 2 CN, R24 independently of R21, has the same meanings as R21, or H, CN, COCH 3 , COOH, COOR21, CONR21R22, NH 2 , NHCOR21, 107 R25 independently of R21, has the same meanings as R21, or H, CN, COCH 3 , COOH, COOR21, CONR21R22, NH 2 , NHCOR21, R24, R25 together with the N, form a ring with 4, 5, 6, 7, or 8 members, which may optionally contain still another heteroatom selected from the group N, 0, S, R3 means H, F, Cl, Br, I, OH, OR31, NO 2 , NH 2 , NHR31, NR31R32, NHCHO, NHCOR31, NHCOCF 3 , CH 3 -mhalmn (with hal = Cl, F, particularly F, and m = 1, 2, 3), OCOR31, R31, R32 are independently Ci-C 6 alkyl, or R31 and R32, together with the N, form a ring with 4, 5, 6, 7, or 8 members, which may optionally contain still another heteroatom selected from the group N, 0, S, R5 means H, Ci-C 2 0 alkyl, cycloalkyl, C 2 -C 2 0 alkenyl, C 2 -C 1 O alkinyl, C-C 4 alkylcycloalkyl, heterocycloalkyl, C-C 4 alkylheterocycloalkyl, aryl, Ci-C 4 alkylaryl, heteroaryl, C-C 4 alkylheteroaryl, CmH 2 m+-pYp (with m = I to 6, for o = 1, p = I to 2m+o; for m = 2 to 6, o = -1, p = 1 to 2m+o; for m = 4 to 6, o = -2, p = I to 2m+o; Y = independently selected from the group consisting of halogen, OH, OR5 1, NH 2 , NHR5 1, NR5 I R52, SH, SR2 1), (CH 2 )sCH 2 NHCOR5 1, (CH 2 )sCH 2 NHCSR5 1, (CH 2 )sCH 2 S(O)nR5 1, with n = 0, 1, 2, (CH 2 )sCH 2 SCOR5 1, (CH 2 )sCH 2 0COR5 1, (CH 2 )sCH 2 OSO 2 -R51, (CH 2 )sCH(OH)R51, (CH 2 )sCOOH, (CH 2 )sCOOR51, (CH 2 )sCONR51R52, with s = 0, 1, 2, 3, 4, 5, preferably 0, mono- and di-sugar residues linked through a C atom which would carry an OH residue in the sugar, wherein the sugars are independently selected from the group consisting of glucuronic acid and its stereo isomers at all optical atoms, aldopentoses, aldohexoses, including their desoxy compounds (as e.g. glucose, desoxyglucose, ribose, desoxyribose), with the mono-sugar residues such as aldopentoses, aldohexoses, including their desoxy compounds (as e.g. glucose, desoxyglucose, ribose, desoxyribose) being preferred, with R5 1, R52 which are capable of independently adopting the meaning of R2 1, R22, R4, R6, R7 independently mean H, C-C 6 alkyl, CO-R41, 108 R41 independently from R2 1, has the same meanings as R2 1, X means 0, S, NH, N-R8, wherein R8 independently from R5 may adopt the same meaning as R5, or R5 and R8, together with the N, form a ring with 4, 5, 6, 7, or 8 members, which may optionally contain still another heteroatom selected from the group N, 0, S, or X-R5 may together be H, Y means 0, S, NR9, wherein R9 may be H or CI-C 6 alkyl, as well their stereoisomers, tautomers, and their physiologically tolerable salts or inclusion compounds, wherein the residues for Formula Ia may not concomitantly adopt the following meaning, except in case of cyclodextrin inclusion compounds: RI: H, CI-C 6 alkyl, R2: CI-C 6 alkyl, C 2 -C 6 alkenyl, R3: H, R4 and R6 identical, and independently H, CI-C 6 alkyl, CO-R41, with R41 being Ci-C 6 alkyl, aryl, and R7 being H, Ci-C 6 alkyl, Y: 0, and for Formula Ib: RI: H, R2: pentyl, I -pentenyl, 3-pentenyl, 1,3-pentdienyl, R3: H, R4 and R6 being H, and X-R5 being methoxy, Y: 0.
2. The compounds according to claim 1, wherein Formula la or Ib adopts the stereochemistry of Formula Ila or lIb 109 O R5 R7 Y 6%% R4 R1N R2 Ila R3 HO R7 OH I R2 R3 lib
3. The compounds of Formula Ia, Ib, Ila, Ilb according to claim 1 or 2, wherein the residues R to R2 have the above indicated meanings, and wherein R2 has a water solubility that is at least two times higher, preferably at least five times higher, more preferred at least ten times higher, particularly preferred at least fifty times higher, particularly hundred times higher, or even five hundred times higher compared to R2 being CH=CH-CH=CH CH 3 , with all other residues being maintained.
4. The compounds according to one of the claims I to 3, wherein R3 means F, Cl, Br, I, OH, OR3 1, NO 2 , NH 2 , NHR3 1, NR3 1 R32, NHCHO, NHCOR3 1, NHCOCF 3 , CH 3 -,mhalm (with hal = Cl, F, particularly F, and m = 1, 2, 3), OCOR31.
5. The compounds according to one of the claims 1 to 4, wherein R3 means (CH 2 )rCHO, (CH 2 )rCH=NOH, -(CH 2 )rCH=NOR21, (CH 2 ),CH=NOCOR21, (CH 2 )rCH=NOCH 2 CONR21R22, (CH 2 )rCH=NOCH(CH 3 )CONR2 1 R22, (CH 2 )rCH=NOC(CH 3 ) 2 CONR2 1 R22, (CH 2 )rCH=N-NHCO-R23, (CH 2 )rCH=N NHC(O)NH-R23, (CH 2 )rCH=N-NHC(S)NH-R23, (CH 2 )rCH=N-NHC(NH)NH-R23, 110 (CH 2 ),CH=N-NHC(NH)-R23, (CH 2 )rCH=N-NHCO-CH 2 NHCOR21, (CH 2 )rCH=N-0 CH 2 NHCOR21, (CH 2 )rCH=N-NHCS-R23, (CH 2 )rCH=CR24R25 (trans or cis), N (CH 2 )rCH=NR2 1, (CH 2 )rCH=N-NR2 1 R22, R, and the (CH 2 ) chain elongated residue (CH 2 )rCH=N-N-(C 3 NX'R21 1R212R213R214) (with X' = NR215, 0, S, and R21 1, R212, R213, R214, R215 being independently H or CI-C 6 alkyl), (CH 2 )rCH=N-NHSO 2 aryl, (CH 2 )rCH=N-NHSO 2 heteroaryl, with r = 0, 1, 2, 3, 4, 5, preferably 0.
6. The compounds according to one of the claims 1 to 5, wherein X means N or S, or X-R5 is OH.
7. The compounds according to one of the claims 1 to 6, wherein RI means H, Ci-C 5 alkyl, cycloalkyl, especially H, R2 means CI-Cs alkyl, C 1 -C 4 alkylaryl, C 2 -C 5 alkenyl, heteroaryl, C I-C 4 alkylheteroaryl, CHF 2 , CF 3 , polyol side chain, particularly CHOH-CHOH-CHOH-CHOH CH 3 , CHOH-CHOH-CH=CH-CH 3 , CH=CH-CHOH-CHOH-CH 3 , CH 2 Y (Y = F, Cl, Br, I), CH 2 NH 2 , CH 2 NR21R22, CH 2 NHCOR23, CH 2 NHCSR23, CH 2 SH, CH 2 S(O)nR21, with n 0, 1, 2, CH 2 SCOR21, particularly CH 2 OH, CH 2 OR21, CH 2 OSO 2 -R21, particularly CHO, CH(OR21) 2 , CH(SR21) 2 , CN, CH=NOH, CH=NOR21, CH=NOCOR21, CH=N-NHCO R32, CH=CR24, R25 (trans or cis), particularly COOH (particularly their physiologically tolerable salts), COOR21, CONR2IR22, -CH=NR21, -CH=N-NR21R22, N ,(with X'= NR215, 0, S, and R21 1, R212, R213, R214, R215 being independently H or Ci-C 6 alkyl), -CH=N-NHSO 2 aryl, -CH=N-NHSO 2 heteroaryl, CH=N-NHCO-R23, R21, R22 independently mean CI-C 6 alkyl, cycloalkyl, aryl, CI-C 4 alkylaryl, heteroaryl, Ci-C 4 alkylheteroaryl, l11 R23 independently of R2 1, has the same meanings as R2 1, or CH 2 -pyridinium salts, CH 2 -tri-Ci -C 6 alkylammonium salts, R24 independently of R21, has the same meanings as R21, or H, CN, COCH 3 , COOH, COOR21, CONR21R22, NH 2 , NHCOR21, R25 independently of R21, has the same meanings as R21, or H, CN, COCH 3 , COOH, COOR21, CONR21R22, NH 2 , NHCOR21, R24, R25 together mean C 4 -C 8 cycloalkyl, R3 means F, Cl, Br, 1, NO 2 , NH 2 , NHCOR3 1, R31 independently means C I-C 6 alkyl, R5 means H, CI-C 6 alkyl, particularly Ci-C 3 alkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkenyl, C 1 -C 6 alkenyl, CI-C 6 alkinyl, C)-C 4 alkylcycloalkyl, heterocycloalkyl, Ci-C 4 alkylheterocycloalkyl, aryl, Ci-C 4 alkylaryl, heteroaryl, C 1 -C 4 alkylheteroaryl, CmH 2 m+o P (with m = I to 6, for o =1, p = I to 2m+o; form = 2 to 6,o = -1, p = I to 2m+o; form = 4 to 6, o = -2, p = 1 to 2m+o; Y = independently selected from the group consisting of halogen, OH, OR21, NH 2 , NHR21, NR21R22, SH, SR21), particularly preferred is hydroxyalkyl with one or more OH groups, R4, R6, R7 independently mean H, Ci -C 5 alkyl, CO-R41, R41 independently from R21, has the same meanings as R2 1, X means 0, S, NH, N-R8, Y means 0, S.
8. The compounds according to one of the claims 1 to 7 in the form of inclusion compounds with cyclodextrin, particularly alpha-cyclodextrin. 112
9. A fredericamycin derivative substantially as hereinbefore described with reference to Tables I to 6.
10. A pharmaceutical composition comprising a compound according to any one of 5 claims 1 to 9, and a pharmaceutically acceptable dilutent, excipient, carrier and/or adjuvant.
11. The derivative according to claim 9 in combination with at least one further agent for tumor treatment. 10
12. The use of a compound according to one of claims 1 to 9 for preparation of drugs for tumor treatment, particularly of those that can be treated by inhibition of the topoisomerases I and/or II, and by which apoptosis is induced. 15
13. The use of a compound according to any one of the claims 1 to 9, or compounds in which the following meanings can be concomitantly adopted in case of Formula Ia: R1: H, Ci-C 6 alkyl, R2: C 1 -C 6 alkyl, C 2 -C 6 alkenyl, R3: H, R4 and R6 identical, and independently H, CI-C 6 alkyl, CO-R41, with R41 being C 1 -C 6 alkyl, aryl, and R7 being H, C 1 -C 6 alkyl, and in case of Formula Ib: RI: H, R2: pentyl, 1-pentenyl, 3 20 pentenyl, 1,3-pentdienyl, R3: H, R4 and R6 being H, and X-R5 being methoxy, for preparation of drugs for treatment of parasites.
14. The use of a compound according to any one of the claims 1 to 9, or compounds in which the following meanings can be concomitantly adopted in case of Formula Ia: 25 R1: H, C 1 -C 6 alkyl, R2: C 1 -C 6 alkyl, C 2 -C 6 alkenyl, R3: H, R4 and R6 identical, and independently H, C 1 -C 6 alkyl, CO-R41, with R41 being CI-C 6 alkyl, aryl, and R7 being H, C 1 -C 6 alkyl, and in case of Formula Ib: R1: H, R2: pentyl, 1-pentenyl, 3 pentenyl, 1,3-pentdienyl, R3: H, R4 and R6 being H, and X-R5 being methoxy, for preparation of drugs for immunosuppression. 30
15. The use of a compound according to any one of the claims 1 to 9, or compounds in which the following meanings can be concomitantly adopted in case of Formula Ia: 113 R1: H, CI-C 6 alkyl, R2: Ci-C 6 alkyl, C 2 -C 6 alkenyl, R3: H, R4 and R6 identical, and independently H, CI-C 6 alkyl, CO-R41, with R41 being CI-C 6 alkyl, aryl, and R7 being H, CI-C 6 alkyl, and in case of Formula Ib: RI: H, R2: pentyl, 1-pentenyl, 3 pentenyl, 1,3-pentdienyl, R3: H, R4 and R6 being H, and X-R5 being methoxy, for 5 preparation of drugs for treatment of neurodermitis.
16. A process for preparing the derivative of claim 9, substantially as hereinbefore described with reference to the Examples. 10
17. A method of treating a tumor in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a compound of any one of claims 1 to 9 or the composition of claim 10 or claim 11.
18. A method of treating a mammal suffering from a condition associated with 15 immunosuppression, the method comprising administering to the mammal a therapeutically effective amount of a compound of any one of claims 1 to 9 or the composition of claim 10.
19. A method for treating a parasitic infection in a mammal, the method comprising 20 administering to the mammal a parasiticly effective amount of a compound of any one of claims 1 to 9 or the composition of claim 10.
20. A method of treating neurodermitis in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a compound of 25 any one of claims 1 to 9 or the composition of claim 10.
AU2010200034A 2002-03-26 2010-01-05 Fredericamycin derivatives Ceased AU2010200034B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2010200034A AU2010200034B2 (en) 2002-03-26 2010-01-05 Fredericamycin derivatives

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DE10213580 2002-03-26
DE10213580.0 2002-03-26
DE10248451A DE10248451A1 (en) 2002-03-26 2002-10-17 Fredericamycin derivatives
DE10248451.1 2002-10-17
AU2003219088A AU2003219088A1 (en) 2002-03-26 2003-03-20 Fredericamycin derivatives
AU2010200034A AU2010200034B2 (en) 2002-03-26 2010-01-05 Fredericamycin derivatives

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU2003219088A Division AU2003219088A1 (en) 2002-03-26 2003-03-20 Fredericamycin derivatives

Publications (2)

Publication Number Publication Date
AU2010200034A1 true AU2010200034A1 (en) 2010-01-28
AU2010200034B2 AU2010200034B2 (en) 2011-06-02

Family

ID=27815967

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010200034A Ceased AU2010200034B2 (en) 2002-03-26 2010-01-05 Fredericamycin derivatives

Country Status (5)

Country Link
EP (1) EP2172457A3 (en)
AU (1) AU2010200034B2 (en)
CA (1) CA2761440C (en)
DE (2) DE10248451A1 (en)
DK (1) DK1503988T3 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673768A (en) 1983-02-24 1987-06-16 Du Pont Canada Inc. Separation of polymer from hydrocarbon solvent in the manufacture of polymers of ethylene
US4584377A (en) * 1983-08-18 1986-04-22 Ss Pharmaceutical Co., Ltd. Novel Fredericamycin A derivatives
JPS6144868A (en) * 1984-08-09 1986-03-04 Ss Pharmaceut Co Ltd Novel frediricamycin a derivative
US4673678A (en) * 1986-07-25 1987-06-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble derivatives of fredericamycin A
US5166208A (en) * 1991-10-09 1992-11-24 Boston College Fredericamycin A derivatives
JP4351310B2 (en) 1998-08-31 2009-10-28 泰行 北 Novel spiro polycyclic compound and method for producing the same

Also Published As

Publication number Publication date
CA2761440A1 (en) 2003-10-02
CA2761440C (en) 2013-07-09
DE10248451A1 (en) 2003-10-09
DK1503988T3 (en) 2009-11-23
AU2010200034B2 (en) 2011-06-02
DE50311730D1 (en) 2009-09-03
EP2172457A3 (en) 2010-07-21
EP2172457A2 (en) 2010-04-07

Similar Documents

Publication Publication Date Title
US8247424B2 (en) Fredericamycin derivatives
AU2003250017B2 (en) Fredericamycin derivatives as medicaments for treating tumours
AU2003222785B2 (en) Fredericamycin derivatives
US20080318942A1 (en) Fredericamycin Derivatives
EP2097411B1 (en) 3 -amino-imidazo [1,2 -a]pyridine derivatives having an sglt1 and sglt2 inhibiting action, for treating type 1 and type 2 diabetes
AU1641592A (en) Crystalline tiagabine hydrochloride monohydrate, its preparation and use
AU2010200034B2 (en) Fredericamycin derivatives
CA2421219A1 (en) Arylpiperazine derivatives and their use as psychopharmaceuticals
JPS5838299A (en) Aminoglycoside derivative, manufacture and medicinal composition
CN112194654B (en) Benzimidazole-containing myricetin derivative, preparation method and application
ES2660876T3 (en) Pyridone derivatives as inhibitors of acid secretion and process for preparing them
CN106800538B (en) Benzimidazole derivative and synthetic method thereof
CN112778285A (en) Preparation method of pantoprazole impurity
DE102006005937A1 (en) New fredericamycin derivatives are topoisomerase I inhibitors useful to treat tumor, parasite, immunosupression and neurodermititis

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY THE EXAM REQUEST FEE HAS BEEN EXTENDED TO 26 OCT 2010.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired